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Abstract (English) 
Parenteral nutrition (PN) offers the possibility to increase or to ensure nutrient intake, providing 
nutrients in sufficient doses to meet the veterinary and human patient’s daily requirements. PN is a 
complex admixture based on amino acids, dextrose, lipids. Safety issues related to parenteral nutrition 
formulations have led to the development of guidelines for safe practices. The development of new 
formulation and the evaluation of the already used solution is the main research in PN practice. 
International guidelines are quite vague regarding the optimal doses of amino acid to administer to 
malnourished patients affected by liver desease. A decreased ratio of branched-chain amino acids 
(BCAA) to aromatic amino acids (AAA) is considered an important pathogenetic factor in hepatic 
disease. The PN solution are composed by different compound, where the BCAAs are always 
presents. Long-term oral supplementation with branched chain amino acids (BCAAs) as adjuvant 
during liver injuries, both in humans and animals, is still not totally clear. Aim of the present study 
was to determine how amino acids in PN and BCAAs on an in vitro study can preserve liver damage 
and function. First purpose of this study was to evaluate the use of partial parenteral nutrition (PPN) 
in dogs, using two different solutions:  11 dogs treated with a normal amino acidic concentration 
(Medium/Low Protein Level group, Freamine concentration ≤ 25%;1,9-2,2 gr/kg/die amino 
acids/proteins) as control group and 9 dogs with high-amino acid percentage (High Protein Level 
group, Freamine > 25%; 3,6-6 gr/kg/die amino acids/proteins) as cases. The evaluation of the two 
differents solutions is based on the liver damage during the therapy. Results reveal a not statistically 
significatives differencies for liver damage between High Protein Level group and Medium/Low 
Protein Level group. It means that an a hight amount of amino acids in PN could not affect and 
overload the hepatic metabolism, despite carrying out their more advantage effects on body lean mass.   
 The second purpose and study, which is the most importan for us, was to evaluate two differents in 
vitro models selected: A) hepatic rabbit cells plated in 2D monolayer and B) rabbit hepatic cells 
cultured onto 3D scaffolds, obtained from decellularized rabbit liver. Both A and B cells were treated 
with BCAAs. All cells adhered and proliferated, once plated. Moreover, the presence of hepatic 
progenitors (HPCs), were detected by immuno staining assay and mRNA expression. However, A 
cells were shown to produce albumin and FVII but quickly entered G0 and arrested growth by day 
15. In contrast, cells in B, actively replicated and recellularized ECM rabbit liver, mimicking the 
original organ cyto-architecture, until day 21. Interestingly, under defined conditions, BCAA 
supplementation promoted vigorous growth of cell organoid and increased hepatocyte albumin and 
FVII production and expression. A selective amplification of self-renewing bi-potent HPCs was also 
observed. These results highlight the role of BCAAs in long term supplementation and support the 
use of 3D cultures as reliable in vitro models. In conclusion, these finding suggest that an high amino 
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acidic diet with a high BCAAs/AAA ratio coud be a valid therapeutic option in cachectic patients or 
patient with severe livere diseases.   
  
Abstract (Italiano) 
La nutrizione parenterale (PN) offre la possibilità di aumentare o di assicurare l'assunzione di 
nutrienti, fornendo sostanze nutritive in dosi sufficienti a soddisfare le esigenze quotidiane del 
paziente in medicina e in medicina veterinaria. La PN è una miscela complessa composta da 
aminoacidi, glucosio e lipidi. Le criticità di sicurezza relative alla composizione delle formulazioni 
parenterali hanno portato allo sviluppo di linee guida per una pratica clinica sicura. Infatti, lo sviluppo 
e lo studio delle diverse soluzioni argomento principale delle ricerche pubblicate in questo ultimo 
decennio. Purtroppo, però, le linee guida internazionali sono abbastanza generaliste riguardo le dosi 
ottimali e qualitative della porzione aminoacidica somministrata in pazienti malnutriti e affetti da 
malattie epatiche. Un ridotto rapporto tra amminoacidi a catena ramificata (BCAA) e aminoacidi 
aromatici (AAA) è considerato un importante fattore patogenetico durante patologie che affliggono 
il fegato o in caso di grave cachessia. Per codesto motivo, le soluzioni utilizzate e commercializzate 
i BCAA sono sempre presenti. L'integrazione orale a lungo termine con BCAA come adiuvante 
durante affezioni epatiche, sia negli esseri umani che negli animali, non è ancora del tutto chiara. Il 
primo scopo del mio progetto di dottorato è stato quello di valutare l'uso della nutrizione parenterale 
parziale (PPN) in cani ospedalizzati, utilizzando due differenti soluzioni: 11 cani trattati con una 
normale concentrazione aminoacidica (gruppo Medium / Low Protein Level, concentrazione di 
Freamine ≤ 25%, 1, 9-2,2 gr / kg / die aminoacidi / proteine) e 9 cani con percentuale aminoacidica 
alta (gruppo High Protein Level, Freamine> 25%, 3,6-6 gr / kg / die aminoacidi / proteine). La 
valutazione è stata basata sull’individuazione di un eventuale danno epatico durante la terapia 
nutrizionale. I risultati hanno rivelato una differenza tra il gruppo High Protein Level e il gruppo 
Medium / Low Protein Level non statisticamente significativa per danno epatico. Questo risultato ci 
permette di valuare un probalbile utilizzo di una PN ad alto contenuto aminoacidico migliorando le 
condizioni di cachessia o perdità muscolare senza sovraccaricare il metabolismo epatico. Il secondo 
scopo di questa tesi è stato la valutazione di concentrazioni differenti di BCAA in due diversi modelli 
in vitro: A) cellule epatiche di coniglio coltivate in un monostrato 2D e B) cellule epatiche di coniglio 
coltivate su scaffold decellularizzato. Le cellule A hanno dimostrato di produrre albumina e fattore 
sette (FVII) ma sono entrate in G0 rapidamente e hanno arrestato la crescita entro il giorno 15. Le 
cellule B, invece, si sono replicate attivamente e hanno ricellularizzato l’ECM del fegato di coniglio. 
L'integrazione di BCAA ha promosso la crescita dell’organoide e hanno permesso aumento di 
produzione di albumina di FVII. È stata osservata, inoltre, un'amplificazione selettiva delle HPC. 
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Questi risultati hanno evidenziano il ruolo dei BCAA nell'integrazione a lungo termine come 
sostengno di colture 3D e il loro particolare ruolo protettivo in corso di patologie epatiche. 
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The anabolic response to severe injury releases a high amount of amino acids from muscle1 into the 
general circulation, endowing new protein synthesis at the sites of tissue injury to optimized immune 
function and regulate the inflammatory response. The cost of this rapid body protein remodeling is 
anabolic inefficiency: the net loss of muscle protein exceeds protein mass gain elsewhere and the 
balance of whole nitrogen becomes strongly negative2–7. During early starvation, hepatic 
glycogenolysis and gluconeogenesis are increased to maintain blood glucose levels. In humans, 
hepatic glycogen stores are depleted within 24 hours8,9. Dogs deplete hepatic glycogen stores more 
slowly than humans, showing peak depletion between the second and third day of fasting9. After 
glycogen depletion, skeletal and visceral body proteins are broken down to provide amino acid 
precursors for gluconeogenesis10. This results in nitrogen loss and negative net nitrogen balance11. If 
starvation continues for more than several days in humans, the metabolic rate decreases, decreasing 
energy requirements. There is enhanced oxidation of fat, decreased breakdown of protein, and the 
development of ketosis. In healthy fasting dogs, fat mobilization progresses more slowly, and ketosis 
is milder than in human beings12. Fasting dogs also have efficient peripheral utilization of ketones 
more than humans; the contribution of ketone bodies to energy requirements increases from 7 per 
cent after an overnight fast to 13% after 10 days of starvation. The decreased energy requirements 
and increased utilization of fat for energy help decrease the use of protein for gluconeogenesis, 
sparing body protein. There are, however, still obligate glucose requirements for the renal medulla, 
bone marrow, circulating blood cells, and central nervous system, where the energy supply is obtained 
from continued protein catabolism12. Plasma amino acid concentrations could provide insight into 
this process, but they vary widely in critical illness, being affected by the phase and intensity of the 
injury response; the patient’s existing nutritional, metabolic, and hemodynamic status; and the 
characteristics of the nutritional therapy provided. When measured in previously normal or not 
cachectic patients after successful fluid resuscitation and before exogenous nutrient provision, plasma 
nonessential amino acid concentrations are usually low and essential amino acid concentrations are 
either normal or low13–20. But circulating amino acid concentrations show only a static view of what 
is a highly dynamic process. Amino acid concentrations could be increased by intense net muscle 
proteolysis or inadequate liver uptake and metabolism in the setting of liver hypoperfusion or 
metabolic failure17, 21,22, or they could be reduced despite a high rate of release from muscle that is 
still insufficient to match the combined rates of central protein synthesis, gluconeogenesis, and 
immediate amino acid catabolism, all of which are accelerated in critical illness. We can’t argue that 
dietary protein deficiency is a common condition in acutely hospitalized patients, and universal in 
critical illness. In fact, inattention to these nutritional deficiencies leads to the disease called protein-
energy malnutrition, the cardinal features of which are generalized muscle atrophy and fat loss. 
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Modern hospitalized patients have adequate (or more than adequate) fat reserves to draw upon during 
temporary periods of hypocaloric nutrition so muscle loss is considered much more dangerous than 
fat loss. The decrease of lean body mass despite to fat reserve is a life-threatening, debilitating and a 
difficult to reverse status. In addition to the muscle atrophy caused by deficient dietary protein and 
energy provision, many diseases or their treatments increase dietary protein requirements well above 
normal by increasing body amino acid or protein loss (in wound exudates or fistulas, inflammatory 
diarrhea, and renal replacement therapy) or by pathologically increasing muscle protein catabolism, 
as occurs with high-dose glucocorticoid therapy and as part of the systemic inflammatory response 
to sepsis and major trauma. In the last forty years has been a consensus in the literature and in the 
studies about N balance that critical illness increases human protein requirements23–31. Unfortunately, 
defined and hard data can’t confirm or refuse the conclusion about the benefits of protein calorie 
supplementation. The results have been very conflicting. Peptide bond formation is a dehydration 
reaction. For this reason, free amino acids contain less protein substrate, and less energy, than the 
proteins they create32. For example, 100 g of hydrated mixed amino acids does not provide 400 kcal 
and 100 g protein but only 340 kcal and 83 g of protein, which substrate is formed by isoleucine, 
leucine, lysine, methionine, phenylalanine, threonine, tryptophan and valine). Arginine is 
synthesized, but not always in a sufficient amount but it is considered conditionally essential. Another 
eight amino acids (alanine, asparagine, aspartate, glutamate, glutamine, glycine, proline—actually an 
imino acid—and serine) are nonessential because they are readily synthesized from widely available 
intracellular carbohydrate molecules and amine groups in the large, rapidly interconverting pool of 
free non-essential free amino acids (NEAAs), predominantly glutamine, glutamate and alanine. The 
hypothesis that continues to await rigorous testing is that prompt, high-protein (2–2.5 g/kg per day 
human, 3-6 g/kg per day dogs) hypocaloric nutrition may improve clinical outcomes in catabolic 
critical illness. Early protein provision should be increased to somewhere between 1.5 and 2.5 g 
protein/kg normalized dry body weight per day23-25 in humans. Patients who have a faster and more 
massive protein loss are evaluated and studied starting from the loss of N through the renal filter and 
then in the urine. These patients are the ones who can mostly takes advantages from suitably protein 
provision33. In veterinary medicine there are no precise data about the maximum dosage of protein in 
the diet during states of cachexia, remembering that the normal daily doses are 3 g protein /kg for 
dogs and 6 g protein/kg for cat34,35. Therefore, it is important to understand how nutrients can reach 
the blood system and bring energy to the various biological systems. When the gastrointestinal tract 
is functional, enteral nutrition is the preferred method of nutritional supplementation because it 
preserves the integrity of the gut mucosal barrier and function and is easier and less expensive than 
other methods such as parenteral nutrition (PN)36. PN can be classify as: Total parenteral nutrition 
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(TPN) and Partial parenteral nutrition (PPN) (sometimes the term PPN is commonly use also to 
indicate peripheral parenteral nutrition).  TPN is recommended when the gastrointestinal tract is not 
functional, or it is undesirable to use it, like severe malabsorption, prolonged ileus, and after some 
gastrointestinal surgeries37. The solutions used in TPN are usually a combination of glucose, amino 
acids and lipids. Owing to the high osmolality (greater than 800 mOsm litre–1) of TPN solutions it 
has been recommended that they be administered through a central vein to prevent peripheral vein 
thrombosis. Disadvantages of using TPN include cost, necessity (and difficulty) of accessing and 
maintaining a central venous catheter, risk of infection or central vein thrombus, and metabolic 
disturbances. These difficulties and disadvantages limit the use of TPN in veterinary practices. The 
goal of PPN is to spare breakdown of endogenous tissue and visceral proteins by providing an energy 
source such as glucose or lipids, and/or by providing amino acids that are catabolized for energy and 
used for protein synthesis without overload the cells metabolism of each single organ. In fasting 
human patients, infusion of 5 per cent glucose solution is proposed to decrease nitrogen loss because 
the solution partially fulfills energy requirements and reduces the amount of glucose that must be 
produced by gluconeogenesis36. Administration of 5 per cent glucose solutions has been proposed to 
be useful for protein sparing in veterinary patients and in humans36.  but conversely, other authors 
consider it to have little protein sparing effect for veterinary patients due to the small amount of 
energy provided37.  It has been known that administration of amino acids stimulates resting energy 
expenditure and hence thermogenesis38, even during general anaesthesia39 . In humans and rats, it has 
been shown that amino acid infusion causes nutrient- induced thermogenesis as a result of heat 
production in skeletal muscle and prevents reduction in metabolism and hypothermia during 
anaesthesia39-41. Moreover, studies using anaesthetized rats showed that administration of amino acids 
increases the plasma insulin concentration and the anabolic effect of insulin on muscle42. These 
findings suggest that amino acids facilitate heat generation and retention in the body. The metabolic 
and thermogenic effects of amino acid infusion have also been studied in dogs43-44. However, a 
clinically useful infusion protocol has yet to be established, because adequate dose and treatment 
practices for infusion of amino acids are unknown especially in animals. Talking about differences 
between veterinary and human medicine, over the years, the PN has been the subject of controversies 
regarding the use of standard or specific formulas for the individual patient. Many human hospital 
pharmacies purchase premixed ready-to-use PN products that are either dual-chamber (amino acids 
and dextrose, with or without electrolytes) or triple-chamber (amino acids, dextrose and lipid). 
Shortly prior to infusion, the internal membranes separating the chambers are broken, their contents 
intermixed and vitamins, trace minerals and additional electrolytes added45,46. These products are 
convenient and potentially cost-effective, but their fixed nutrient composition is a drawback. In 
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veterinary medicine and in some cases like for home PN the compositions can be selected and can 
meet the specific needs of each patient, mixing the three compound as amino acids, dextrose and lipid 
directly in a single bag or bottle. In this case, it is possible to meet a patient’s protein requirement and 
avoid calorie overfeeding by selecting an appropriate fixed-composition product. The downside of 
this approach is the inconvenience of stocking the pharmacy with many different premixed products. 
In some situations—especially critical illness, in which 2.5 g/kg protein substrate per day may be 
required47. Diets high in protein pose a potential acid load to the liver, mainly as sulfates and 
phosphates. It was hypothesized that calcium and hence bone mass was lost in order to buffer this 
acid load. the protein-induced acid-load to the liver remains, e.g. as sulfuric acid from the oxidation 
of methionine and cysteine48. Rigorous data on the comparative efficacy of various formulations of 
parenteral nutrition, the optimal timing of administration, and the role of specific clinical factors (e.g. 
blood glucose control) on clinical outcomes with different parenteral nutrition formulations are 
lacking49. Standard amino acid solutions contain all nine essential amino acids in patterns and 
amounts designed to match or exceed their recommended dietary allowances, sufficient amine N from 
some NEAAs to support the synthesis of all them, and a generous amount of arginine47. The 
recommended normal adult protein requirement is 0.8 g/kg per day. To meet this requirement a 
parenteral amino acid solution must be infused at the rate of ~1.0 g/kg per day. Specialized amino 
acid solutions are available for patients with hepatic insufficiency (increased amounts of branched-
chain amino acids and less methionine, phenylalanine and tryptophan), renal insufficiency (essential 
amino acids largely or only), and protein-catabolic critical illness (increased branched-chain amino 
acids). The properties of the branch-chain amino acids (valine, leucine, isoleucine) as energy 
substrates, substrates for gluconeogenesis, and modulators of muscle protein metabolism make the 
use of branch-chain amino acids-enriched solutions theoretically appropriate for the management of 
the metabolic alterations that occur in cachexia and sepsis50. The in vitro and in vivo animal data 
available have suggested a benefit for the branch-chain amino acid on protein synthesis and 
degradation in sepsis. Branch-chain amino acids-enriched solutions (45%) increase the rate of hepatic 
protein synthesis and acute-phase proteins in critically ill patients. These proteins may be important 
in host defense mechanisms against infection. Thus, the administration of solutions containing a high 
proportion of branch-chain amino acid may improve the chances of survival for such patients via this 
mechanism51. The use of high concentrations of various amino acids in the diet may perturb neoplastic 
cell growth and liver dysfunction. To date, the most effective amino acid for this purpose either in 
cell culture and in vivo has been arginine and branched-chain amino acids (BCAAs)50. In human 
medicine, certain liver neoplastic conditions and liver insufficiency are often accompanied by 
changes in metabolism resulting in cachexia. Studies have suggested that branched-chain amino acids 
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may help to preserve lean body mass in models of muscle atrophy51–53. More recent studies suggest 
that leucine has profound effects upregulating signaling events (i.e., mTOR activation), leading to 
protein synthesis in skeletal muscle54. The exact mechanisms for this upregulation remain elusive, 
but treatment with branched-chain amino acids (BCAAs) remains attractive as a therapeutic modality 
for ameliorating lean body mass in cachectic patients. BCAAs are beneficial during cachexia and 
hepatic failure determining their effects on neoplastic cell growth is important. Neoplastic cell lines 
(canine osteosarcoma, canine bronchoalveolar carcinoma, and Madine-Darby canine kidney cells) 
under the influence of high concentrations of BCAAs (leucine, isoleucine, valine) were examined for 
their ability to augment or diminish cell growth. Branched chain amino acids (BCAA) have been 
shown to affect gene expression, protein metabolism, apoptosis and regeneration of hepatocytes, and 
insulin resistance. They have also been shown to inhibit the proliferation of liver cancer cells in vitro 
and ameliorate the hepatic liver cells regeneration and, moreover, are essential for lymphocyte 
proliferation. All these features of BCAAs are studied and evaluated for a new nutrition strategy in 
different human pathologies. In veterinary medicine the use of the BCAAs as integration of a normal 
dietary plan seems to be a valid choice for the same benefit found in human clinical nutrition55. The 
mechanism by which BCAA specifically improves plasma albumin levels is not fully understood yet. 
The synthesis and secretion of albumin increased when rat primary hepatocytes were cultured with 
an appropriate Fischer’s ratio (3.0). The addition of amino acids similar to the plasma composition 
was found to promote albumin synthesis in primary hepatocytes and in liver perfusion experiments56-
59 and the removal of amino acids decreased albumin synthesis59. The first scientist applies the single 
nourishment concept for the total nutritional needs of men and animals was John Harvey Kellogg60. 
To improve the patients’ diet, Kellogg developed, patented, and introduced a variety of new foods, 
including Granola and Corn Flakes; he also invented peanut butter, artificial milk made from 
soybeans, and a variety of imitation meats. His younger brother, Will Keith Kellogg, later built a 
successful company to market his brother’s cereal creations; in so doing, he transformed the average 
American’s breakfast. 
We can evaluate and study different amino acids to achieve a similar Kellogg’s scope: Which is the 
compound/ amino acids that help or overload the liver during TPN or PPN?  
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HYPOTHESIS  
 
1. Detrimental effects of different amount of amino acids solution on dogs’ liver affected by 
different pathologies during parenteral nutrition.  
2. BCAAs protecting role on model of liver failure.  
 
AIMS 
 
Considering the lack of data in the literature in veterinary medicine and the confusion and 
fragmentation of medical studies concerning the use of amino acids in PN the in vivo and in vitro 
studies purpose are1: 
 
1. to evaluate a possible negative effect of a high dosage of solutions amino acidic ready 
prepared on a heterogeneous population of canine patients affected by different pathologies 
that needed parenteral nutritional therapy. 
2. Long-term oral supplementation with branched chain amino acids (BCAAs) as adjuvant 
during liver injuries, both in humans and animals, is still not totally clear. Aim of the present 
study was to determine how BCAAs preserve liver functions in vitro. 
 
 
Summary of the experimental design 
 
The research is divided into two experimental projects:  
1. An in vivo dog clinical model to assess the effects of high-dose amino acids solutions.  
2. An ex vivo model to assess the effect of varying BCAA concentration on liver organoids. 
 
 
The future aim of my PhD project will be to study the effect of the BCAA on the Normothermic 
extracorporeal liver perfusion. The intellectual process is starting from the clinical cases passing 
through an in vitro evaluation by three following steps: monolayer 2D culture, then 3D scaffolds 
culture and at the end the whole organ perfusion as the in vitro model.  
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INTRODUCTION 
Artificial nutrition (AN) is a therapeutic procedure which fully satisfy the nutritional needs of patients 
otherwise unable to feed naturally.  Choosing the way to provide nutrition support is a key step in 
managing critical patients and select the combination of the artificial nutrition for each patient will 
be dictated by clinical conditions and nutritional status, duration of nutritional support as well as 
needs, dietary limitations, and the advantages and disadvantages of each type of nutrition1.  
Restoring an optimal body condition or physiological body weight is not necessarily the goal of 
nutritional support, the main purpose is to preserve lean tissues and organ function rather than 
completely resolving the state of malnutrition, a goal that occurs during convalescence.2 In 
hospitalized patient, malnutrition is the result of an acute or chronic deficiency, both of calories as 
protein, causing the so-called “malnutrition protein-calorie " (MPC), characterized by lean mass loss 
and expansion of extracellular compartment (Tab.1).3 Malnutrition refers to the progressive loss of 
body mass and adipose tissue due to an inadequate intake or increased protein and calories needs; 
possible consequences are: atrophy of organs and muscles, alteration of immune-responsiveness, 
delayed wound healing, anemia, hypoproteinemia, lower resistance to infections and death. The 
patient with protein deficiencies and calories should receive an integration until it is possible to 
eliminate the deficiency causes.4 Malnutrition can be classified as primary or secondary to other 
causes. Primary malnutrition is characterized by the absence of one or more components of a diet, 
such as carbohydrates, fats (fatty acids), protein (amino acids), vitamins and minerals. In secondary 
malnutrition, dietary nutrient intake is adequate, but malnutrition is caused by malabsorption of 
specific nutrients, metabolic deficiencies and accumulation, excessive leakage or increased demand. 
The causes of secondary malnutrition are grouped into three categories, partly overlapping: 
gastrointestinal diseases, chronic cachexia and acute diseases.5 Malnutrition indicators include weight 
loss, hair loss, muscle mass loss, hypoalbuminemia, lipopenia and coagulopathy. These alterations 
are however not specific to malnutrition and often do not appear soon during the process.6 
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Diagnosis of protein-calorie malnutrition 
- weight loss> 10% of normal body weight 
- increase nutrient losses (diarrhea, vomiting, wounds, severe burns) 
- increased nutritional needs (traumas, surgical interventions, infections, burns, fever) 
- anorexia or hyporexia (insufficient intake of food)> 5 days, or situations where it is expected that, 
for more than five days, the animal takes insufficient portions of food 
- increased nutrient requirements (trauma, surgery, infections, burns, fever) 
Table 1. Protein-caloric Malnutrition. 
Simple fasting includes metabolic changes which may occur even in the absence of pathologies. The 
time it takes to metabolic changes and alterations associated with nutrient deficiency, should guide 
the nutrition of hospitalized dog. In fed properly animals, post-prandial nutrients are immediately 
used in metabolic pathways and stored as glycogen, fat and muscle protein. Any excess energy is 
converted into triglycerides deposited as fat in adipose tissue, liver and muscle. In a state of normal 
nutrition, when the serum glucose is high, the liver becomes a glucose importer. Patients with food 
deprivation show a complete reversal of the metabolic processes. Lacking the exogenous source of 
energy, the endogenous resources become the reservoirs to meet the metabolic needs. The glycogen 
storage becomes the primary source of energy and, to preserve for as long as possible the vital 
functions, the animals use stored fat and protein to maintain a constant concentration of glucose in 
the blood. The metabolism of carbohydrates is profoundly altered in the first week of fasting. In the 
early days, the dogs maintain constant blood glucose through glycogenolysis and gluconeogenesis. 
The muscle catabolism releases amino acids, lactic acid and pyruvate to produce glucose in the liver6. 
In an attempt to convert the circulating glucose, the liver releases ketone bodies. These are the product 
of the oxidation of long-chain fatty acids that originate from triglycerides packed in adipose tissue. 
Fatty acids, water insoluble, must be transported in the blood by albumin, while ketones, water 
soluble, have a wide distribution thanks to their ability to cross cell membranes. The insolubility and 
the dependence from the albumin limits the serum concentration of fatty acids. The advantage of the 
conversion of fatty acids into ketones is threefold: ketones are soluble in water, they do not depend 
on the albumin and they can cater to the lipid reserves of the cells for their high blood concentrations. 
Increasing ketones in serum helps to increase the endogenous proteins and glucose. In case of 
starvation ketosis is a correct response of the organism. From the fifth day of fasting decreases the 
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level of insulin and triggers lipolysis in an effort to preserve the stored proteins and maintain the level 
of glucose in the blood for glucose dependent tissues7. From the oxidation of fatty acids, the amino 
acids are partially spared to maintain muscle protein reserves during all the fasting period. Although, 
after two/three days the body proteins are partially spared because the muscles will catalyze the chains 
of amino acids. The reefing management in a patient depends by the number of days of the fasting 
period 8,9. The collapse of protein breakdown is needed to address the imbalance between 
consumption and intake of energy. This catabolic phase continues until the neuroendocrine stimulus 
and the cytokines mediators are removed. Clinically we see the improvement of patients only when 
phase of anabolism starts. In this phase, the body to maintain its homeostasis requires energy and 
proteins. During catabolic fats and proteins are necessary for the patient so the diet will be 
administered with fewer carbohydrates and more protein and fat. Increase fat would lead to electrolyte 
imbalances and hyperglycemia. The phase of hospitalization therefore underlines the constant need 
to re-evaluate the patient to optimize the nutritional plan. However, for long-term fasting is meant the 
state of anorexia in which the patient is in a chronic illness. The ability to respond to this situation 
can be altered in the course of a disease process6,7. While plasma albumin and prealbumin are anti-
inflammatory indicators in humans and their concentration is associated with the development of 
complications and mortality, in the veterinary medicine it is difficult to identify specific laboratory 
data to indicate a condition of malnutrition. Diagnosis of malnutrition can formulate through physical 
examination and some more generic laboratory tests. The number of red blood cells, the content of 
hemoglobin, urea and potassium, the concentration of albumin and total protein, and lipocytes number 
of white blood cells are useful to have a nutritional assessment of the patient and assess his state of 
hydration. Red blood cells, hemoglobin, albumin and total protein have a moderately long half-life, 
from one to eight weeks and they are difficult to evaluate in the early stages of malnutrition, while 
potassium and urea blood levels can be low in the anorexic patients due to the lack of food 
assumption, but urea tends to increase in the final stages of anorexia due to muscles catabolism6-8. 
In human medicine, many tools have been developed to assess the severity of complications, such as 
the Nutritional Risk Index (NRI) that combines albumin and weight loss, Geriatric Nutritional Risk 
Index (GNRI) that considers the current weight with the ideal weight and the Subjective Global 
Assessment (SGA)(Fig.1) 10. 
GNRI = [1489 x albumin (g/L)] + [41,7 x (weight/ideal weight)]  
NRI = [1,489 x albumin (g/L)] + [41,7 x (weight /usual weight)] 
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The best prediction index is the SGA and the value of albumin. The SGA is an excellent prognostic 
factor because diagnose malnutrition, giving emphasis to the causes and the consequences of 
malnutrition. The low albumin concentration (around 3/3.5g/dL) is associated with an increased long-
term mortality. Both albumin and prealbumin pre PN predict the long-term risk of mortality. But to 
have a more precise and accurate prediction, levels of albumin and prealbumin must be integrated 
with GNRI or NRI. First thing to do is to investigate the patient nutritional status with a proper dietary 
history to reconstruct the informations on the diet habits. Than the energy requirement must be 
assessed. 
RER = Resting Energy Requirement = 70x (BW kg) = kcal/die  
PER = Partial Energy Requirement = 70% RER = kcal/die 
RERs are the number of calories required to keep homeostasis resting in a thermally neutral 
environment while the animal is in an absorbing post state. In addition to specific dietary questions, 
the history should also include information regarding appetite, alterations in weight or appearance 
and gastrointestinal symptoms such as vomiting or diarrhea8. Clinical examination including 
nutritional evaluation is a crucial step in identifying the most appropriate nutritional support. Body 
Condition Score (BCS) and Muscle Condition Score (MCS) are the hubs of that assessment. BCS and 
MCS are evaluation criteria based on visible and tactile measurement indices to quantify the level of 
adiposity and muscle development; are parameters that affect the subjectivity of the operator. The 
BCS allows to give a score to the nutritive condition. It is a morphometric system based on inspection 
and palpation of zygomatic crests, thoracic and transverse apophyses of the lumbar and thoracic 
vertebrae, on the ribs and intercostal spaces, on iliac and ischemic tuberosity and on the side ditch to 
quantify the amount of adipose deposits and hence the nutrition status of the animal. A score from 1 
to 5 or from 1 to 9 is assigned, classifying the animal from very thin to obese. The MCS evaluates 
muscle mass and tone through inspection and palpation of the muscular masses of the rear train, 
column, front train, neck and head. Muscle tone is what allows the animal to lift from the decubitus 
and support the body while maintaining the normal relationships between body and limbs; it is the 
degree of resistance that a particular muscle group opposes to the passive movement. Muscle mass 
loss affects resistance, immune response, wound healing and is associated with a higher mortality 
rate11(Fig.3). Clinically, BCS and MCS are not directly related. An animal may be overweight but 
still lose muscle mass. Body weight assessment is used to check if it has remained unchanged or if 
there has been a decrease. Malnutrition can be supposed when a significant involuntary weight loss 
in the past 6 months is greater than 10% to the usual weight, or greater than 5% in one month. In 
absence of habitual weight, malnutrition is indicated by a 20% lowering from the ideal weight12. 
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Abnormal or pathological weight loss should not depend on dehydration, but it should affect muscle 
mass or lean mass. No hematologic parameters such as albumin, prealbumin, potassium and lipocytes 
may be considered in the patient's assessment as their alteration may be indicative of an altered 
nutritional state8. Hypoalbuminemia occurs due to hepatic production deficiency because in 
physiological conditions 50% of the total protein daily synthesis is dedicated to the production of 
albumin, so inadequate protein intake can cause less production of these. However, albumin has a 8-
day half-life in the dog, so before a parameter falls, few days passed since there is a steady decrease 
in protein intake8. Parenteral nutrition (PN) involves administering the intravenous nutritional support 
by attaching a venous catheter to the central or peripheral position, thus bypassing the gastrointestinal 
tract. The PN purpose is to correct the state of malnutrition, prevent progressive caloric-protein 
malnutrition, optimize the patient's metabolic state, minimize the risk of disease, death and 
hospitalization times13. Parenteral nutrition is used in those patients unable to take food spontaneously 
or in which the gastrointestinal tract has to be bypassed due to pathologies or general surgery 
procedure. The decision to undertake a period of parenteral nutrition is based on several parameters, 
often subjective8. PN in the dog is usually used as a short-administration to prevent further nutritional 
deterioration until enteral nutrition restoration. The short duration of the PN, usually intended less 
than 5 days, can reach the goal, in most animals, although, in humans, administration for extended 
periods is reported to lengthen the patient survival9,10. PN can be total or partial. Total Parenteral 
Nutrition (TPN) provides all the daily energy requirement, through a central venous catheter inserted 
into the jugular vein. The power supply for central venous route must be taken into consideration in 
severely catabolic patients, with severe depletion, or simply when TPN for prolonged periods is 
indicated. In order to obtain a positive nitrogen balance, in those patients a calorie-nitrogen ratio of 
at least 100/150 of non-protein calories per gram of nitrogen is advised19. With partial parenteral 
nutrition (PPN) only part of the daily energy, from 40% to 70%, is delivered through a peripheral 
venous route associated with a solid diet per os.. The PPN is indicated in patients with a moderate 
catabolic depletion. The peripheral route of administration is easier to establish using of low 
osmolarity solutions 600/750 mOsmol / L to prevent thrombophlebitis. The osmolarity is the osmotic 
pressure generated by the solutes present in 1 L of solution. It is a physical quantity that measures the 
concentration of the solutions used. In particular is the total number of molecules and ions present in 
one liter of solvent; therefore, expresses the concentration of a solution, emphasizing the number of 
particles dissolved11. The central venous access instead, although more complicated to establish and 
maintain, imposes fewer limitations in the formulation being able to get to 1400 mOsmol / L with a 
lower risk of thrombophlebitis. The parenteral solution is comprised of lipids, dextrose and amino 
acids that compose the "three-in-one solution" or "total nutrient admixture” (TNA) since the three 
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components make up the "one-fluid bag" then a single bag that it represents the Complete solution 
for patient nutrition11-12. Components are always the same but their amount change in relation to the 
subject's RER and the patient's clinical needs. In hand-made PN formula it is important to remember 
that lipid are an excellent substrate for bacterial and fungal growth and it is of fundamental importance 
to follow an aseptic procedure during the preparation, working under hood, wearing sterile gloves, 
needles etc. The PN components can be mixed either manually within a sterile bowl, one at a time 
according to a precise order: glucose, amino acids and lipdis or with an automated system. The 
manual system is certainly the most used and diffused, because it is easily replicable even if slower 
and more susceptible to bacterial contamination than the automated ones. It always starts with the 
dextrose solution, than amino acids, introducing lipids only at the end11. Once prepared, the solution 
can be stored in a 4 ° C refrigerator for up to 3 days14. In qualitative and quantitative determination 
of nutritional needs, the nutritional and metabolic state of the patient, as well as the basic pathology 
and related therapies, must be taken into account. For each macronutrient, the intake must remain 
within well-defined ranges, to avoid errors by defect or excess. First, it is necessary to calculate the 
daily caloric needs specific to the patient, determined by the baseline energy expenditure and the 
degree of physical activity, and varies with the intake of food and pathological conditions. 
Accordingly proteins, lipids and glucose requirements are then calculated14. The daily energy 
requirement (ER) of an animal is given by the intake of proteins, lipids, carbohydrates and fiber. It 
can be calculated as RER. The protein requirement can be calculated as Protein to Calorie Ratio 
(PCR) ratio, which corresponds to the protein g / 1000 kcal EM. 
gr Protein = PCR x RER (Mcal) 
The protein requirement is derived from estimating the amount of high quality protein needed to 
maintain nitrogen balance in the presence of adequate energy input. The needs are different depending 
on sex, age and physiological conditions; while the quality of a protein is determined by comparing 
the quantity of each essential amino acid contained in a certain food with that contained  in a reference 
protein. 
Dog   
PCR  
Cat  PCR 
< 10kg  PCR 55  adult  PCR 70-80  
11/25 kg  PCR 60  senior PCR 80  
26/45 kg  PCR 65  diabetes  PCR > 70  
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> 45 kg  PCR 70  liver failure PCR < 60  
senior PCR > 70  kidney failure   PCR < 60  
gestation PCR > 65  anemia  PCR > 80  
lactation PCR > 75  obesity  PCR > 90  
active PCR > 75  
 
  
Table 2. RPC in dog and cat in physiological and pathological conditions. 
 
 gr/BW kg  PCR Protein to calorie ratio gr/1000 
kcal  
LOW  1,9 - 3  50 - 60  
MEDIUM  3-5  50 - 60  
HIGH  5-7  50 - 60  
Table 3. PCR Classes 
 
Although there is no literature regarding the PCR use in parenteral nutrition, we can consider three 
protein levels: low, medium and high. Proteins are supplied by an amino acid solution with a 
concentration ranging from 3.5% to 15%, with a pH range of 5.3-6.5 and an osmolarity of between 
300 and 1400 mOsmol / L, to which electrolytes can be added if necessary. The most commonly used 
solutions have a concentration of 8.5% with an energy density of 0.34 kcal / ml and osmolarity of 
706/880 mOsmol / L. 44A amino acid solution contains essential amino acids and non-essential 
amino acids such as: L-Isoleucine, L -Leucine, L-Lisin acetate, L-Methionine, L-Phenynalanine, L-
Threonine, L-Tryptophan, L-Valine are essential AAs, while non-essential AAs are L-Alanine, L-
Arginine, L-Proline, L-Serine, L-Cysteine HCl and Acetic Acid45. The range of the proteins to be 
delivered are very wide and vary greatly depending on the patient condition and its eventual 
pathology; it goes from a minimum of 2-3 gr / 100 Kcal to a maximum of 4-5 gr / 100 Kcal for the 
dog, and a range from 3-4 gr / 100 Kcal to 6 gr / 100 Kcal for the cat. It is therefore up to the 
veterinarian to determine the right amount of protein needed for his or her patient, for example 
increasing it in all that situations where a high protein requirement is needed or diminishing it in case 
of kidney or liver failure. Intravenous amino acids are distributed to all organs through the plasma 
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and captured in different quantities as needed. Muscles and liver are the major amino acid regulator 
filters in the blood. Aromatic amino acids (phenylalanine, tryptophan), methionine, lysine and 
threonine are largely captured by the liver, while branched amino acids (leucine, isoleucine, valine) 
are largely captured by the muscles. Part of the amino acids are deaminated, with urea formation, 
while the carbonaceous skeleton is catabolized for energy purposes. The body then needs energy to 
eliminate the excess nitrogen, which could be a problem especially for patients with liver or kidney 
disease and could lead to hyperammonia with clinical signs of encephalopathy, while providing a low 
quantity of amino acids could counteract to lead to hypoalbuminemia, lower immune response, and 
alter the healing times9,15. Here we are to the main point of the use of amino acid during PN. The 
general thought of the hyperproteic diet could contrast the amino acidic lost during cachexia. There 
is no much information about the correct dosage and utilization range both in veterinary medicine 
and medicine in literature but the evidence that the high amino acids amount gave to starved patients 
is a growth in the nutrition science. The researches in experimental animals with liver disease or diet 
protein excess are mainly focused on what a diet can give an improvement in their liver function16-19. 
The general thought is that an hyper protein diet could contrast the amino acidic lost during cachexia, 
but there are not many informations about the correct dosage and range of utilization in either in 
veterinary and human medicine literature, but there is an evidence in nutrition science that an high 
amino acids diet administered to starved patients carries to a better clinical condition. Examples 
comes from some animal studies showing how proteins has a protecting role on the liver in common 
induced hepatic diseases such as alcoholic or nonalcoholic fatty liver16-19. It seems that a high dose 
of amino acids or proteins can counteract the degenerative processes that are on the base of liver 
steatosis. Especially hepatic content of BCAA-derived monomethyl branched-chain fatty acids 
(mmBCFAs) 14-methylpentadecanoic (14-MPDA; valine-derived) and 14-methylhexadecanoic acid 
(isoleucine-derived) where higher in the animal feed with a hyperproteic feed. Liver is the main organ 
handling ingested macronutrients and it is associated with the beginning of different pathologies. The 
science aimed to deepen our knowledge on molecular pathways affected by long-term intake of an 
HP diet. Transcriptome analysis performed on rats liver chronically fed with a casein-rich HP diet 
showed  up-regulated processes related with amino acid uptake/metabolism and lipid synthesis, 
promoting a molecular environment indicative of hepatic triacylglycerol (TG) deposition. Moreover, 
changes in expression of genes involved in acid–base maintenance and oxidative stress indicate 
alterations in the pH balance due to the high acid load of the diet, which has been linked to liver/health 
damage. Up-regulation of immune-related genes was also observed. In accordance with changes at 
gene expression level, we observed increased liver TG content and increased serum markers of 
hepatic injury/inflammation (aspartate transaminase, C-reactive protein and TNF-alpha). Moreover, 
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the HP diet strongly increased hepatic mRNA and protein levels of HSP90, a marker of liver injury. 
Thus, long-term consumption of an HP diet, resulting in a high acid load, results in a hepatic 
transcriptome signature reflecting increased TG deposition and increased signs of health risk 
(increased inflammation, alterations in the acid–base equilibrium and oxidative stress). Persistence 
of this altered metabolic status could have unhealthy consequences16-19. The mechanism by which HP 
diet carry to an eventual improvement of liver function or a limitation of liver damage is still not well 
understood. Beside the positive effect of PN and their inside nutrients, direct damage of parenteral 
nutrition to the liver is mostly focused on lipid overload and the lack of transit of the duodenal ingests. 
The wide spectrum of clinical, biochemical and pathological manifestations may include benign 
increases in liver enzymes to liver disease histologically characterised by centrilobular, intrahepatic 
cholestasis, portal fibrosis, reactive bile duct proliferation, non-specific portal and periportal 
inflammation, and hepatic steatosis. The incidence of hepatic steatosis has decreased thanks to the 
improvements of TPN solutions and technology, including modifications of the TPN regimen, such 
as a greater content of lipids and lesser content of glucose. However, hepatic steatosis still remains 
the most common complication of TPN20. Steatosis consists of a hepatic accumulation of micro- or 
macrovessicular fat associated with metabolic diseases, diabetes, obesity21, drugs and toxins, surgical 
procedures, and parenteral nutrition (PN)22, as well as non-alcoholic steatohepatitis, in which case 
oxidant stress is thought to play a pathogenic role23-24. The precise pathogenesis of TPN-associated 
hepatic steatosis is still unclear. TPN-related hepatic dysfunctions [19] have been linked to oxidant 
stress as well as to genetic25-27, nutritional, environmental and inflammatory factors. More 
specifically, the following nutritional factors have been associated with steatosis and/or 
steatohepatitis: an excessive infusion of glucose or lipids, a carbohydrate to nitrogen imbalance27-33 , 
and the source of infused lipids, an amino acid imbalance, enteral starvation, photo-oxidised products 
of amino acids (AAs)33-40. Increased serum hepatic aminotransferase concentrations have been 
commonly observed within the first 2 to 3 weeks of TPN infusion in upwards of two-thirds of patients. 
Typically, this is a transient increase without significant elevation in serum bilirubin, at least in the 
adult patient. The serum bilirubin concentration often becomes elevated in children, particularly in 
preterm infant. It is important to recognize, however, that serum hepatic aminotransferase 
concentration elevations are both insensitive and nonspecific indicators of hepatic dysfunction. In 
fact, it is not uncommon for a patient to have cirrhosis in the face of normal serum aspartate 
aminotransferase (AST) and alanine aminotransferase (ALT) concentrations. When patients follow a 
longer period of time  receiving TPN, total serum bilirubin concentration tends to increase slightly, 
but more importantly, the AST often increases significantly beginning after approximately 10 weeks. 
The alkaline phosphatase often increases as well, although some of this increase may relate to the 
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development of concomitant metabolic bone disease. In a retrospective study of over 40 long-term 
TPN patients, some of which had received TPN for up to 16 years at the time of the study in 1991, a 
significant correlation between TPN duration and the serum alkaline phosphatase was observed, 
although TPN duration and both AST and ALT were not correlated.66 While it is recognized that liver 
test abnormalities occur during TPN, the question is whether TPN is associated with chronic liver 
disease. Given that the first case of TPN-associated liver disease was described in a young child, it 
comes as no surprise the first case of TPN-associated hepatic failure was described in an infant41. The 
growing need for safe and effective PN therapies to stop the patient have led to a test the correct 
dosages and uses of the amino acid part of the parenteral. Enteral nutrition is preferred to PN for 
invasive nutrition support because of its simplicity, trophic effects on the gastrointestinal tract and a 
possibly reduced risk of infectious complications. PN is more resource-intensive, potentially riskier, 
and requires somewhat more expertise than EN. It is indicated when invasive nutrition support is 
required and EN is refused, inappropriate, or demonstrated (or strongly predicted) to be incapable of 
meeting the patient’s nutritional needs. The major disadvantage of EN in critical illness is its 
slowness. EN commonly fails to achieve the patient’s nutritional goal—especially for protein—
within the first 7–14 days of therapy42. PN’s chief advantage is its ability to deliver a substantial dose 
of amino acids very promptly43. PN’s safety concerns are inadvertent calorie overfeeding, potential 
amino acid over-provision, and a possibly greater risk of infectious complications. However, the 
differences reported in complication rates between EN and PN reflect observations from older studies 
when calorie overfeeding was routine.The justification of the tests for the detection of hepatic damage 
occurs with the selection of appropriate markers. In human and veterinary medicine, there is a fairly 
large overview of liver panels for assessment through blood tests. Hepatocyte cell death during liver 
injury was classically viewed to occur by either programmed (apoptosis), or accidental, uncontrolled 
cell death (necrosis). Growing evidence from the increasing understanding of the biochemical and 
molecular mechanisms involved in cell demise has provided an expanding view of the different kind 
of cell death that can be triggered during both acute and chronic liver damage such as necroptosis, 
pyroptosis, and autophagic cell death. The complexity of non-invasive assessing the predominant 
mode of cell death during a specific liver insult in either experimental in vivo models or in humans 
is highlighted by the fact that in many instances there is significant crosstalk and overlap between the 
different cell death pathways. Nevertheless, the realization that during cell demise triggered by a 
specific mode of cell death certain intracellular molecules such as proteins, newly generated protein 
fragments, or microRNAs are released from hepatocytes into the extracellular space and may appear 
in circulation have spurred a significant interest in the development of non-invasive markers to 
monitor liver cell death. Measurement of serum levels of hepatobiliary enzymes, such as alanine 
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aminotransferase (ALT), the excised aminotransferase (AST), alkaline phosphatase (ALP) and the ɣ-
glutamyl transpeptidase (GGT), total protein (TP) and albumin is commonly used as a screening test 
to detect the presence of hepatobiliary diseases. These enzymes are highly sensitive for the detection 
of hepatobiliary disease, the interpretation is hampered by their lack of specificity towards diseases 
specific disorders40. The central role in the metabolism of the liver and its high blood perfusion mean 
that it is extremely sensitive to secondary damage. So, there are a number of clinical conditions with 
of liver enzymes increase without that there is a damage clinically significant. A marked increase in 
serum levels of the enzymes indicate more substantial hepatobiliary injury but does not necessarily 
imply an unfavorable prognosis. We must consider that in severe chronic liver disease the serum 
levels of the enzymes may be normal or only slightly increased; this occurs due to the replacement 
of the hepatocytes by the fibrosis and / or to the leakage of enzymes organ with consequent depletion 
the total content of the enzymes themselves. Alanine aminotransferase (ALT) is an enzyme specific 
liver cytosol, because the greater amount is present in the liver tissue. Its serum rising therefore occurs 
only in liver disease. The maximum increase of its levels, as serum enzyme activity, it is observed in 
cases of hepatocellular necrosis and acute inflammation. The extent of the raising levels of ALT is 
about proportional to the number of damaged hepatocytes. In dogs, serum ALT may increase in the 
presence of severe necrosis muscle. In dogs under corticosteroid and/or phenobarbital treatment 
increase levels of spherical ALT may be present but it is unclear whether the enzyme elevations 
represent a direct enzymatic induction or reflect a possible hepatotoxicity drug induced. The serum 
ALT it may also increase in case of primary or metastatic liver cancer. The serum aspartate 
aminotransferase (AST) is an enzyme mainly linked to the mitochondria, ubiquitous (myocardium, 
kidney, liver, muscles), so it can increase due to different pathologies not only in case of liver disease. 
It is more sensitive for ALT the identification of hepatobiliary diseases, although it is considerably 
less specific, since significant amounts of this enzyme they are also found in muscle. In general, the 
serum AST increments have a trend parallel to the elevations and, like these, they are associated with 
a spill enzyme resulting in an alteration of membrane permeability. In cases where the serum AST is 
much higher elevations, must be sought muscle origin. Alternatively, since the AST it is present 
within the cytosol and mitochondria, a high ratio ALT: AST may be indicative of severe acute damage 
irreversible. The reference values for the AST are 20/50 IU /l8,40,41. AST and ALT increase, mainly 
hepatocyte necrosis, but also for damage to the cellular function, although a lesser extent. AST and 
ALT are sensitive indicators, capable of identifying the presence of lesions liver even in symptomatic 
patients. Alkaline Phosphatase (ALP) has a low liver specificity, as it is associated with the presence 
of several isoenzymes and a particular sensitivity Pharmacological induction. It locates at the cell 
membrane in the hepatocytes. The ALP isoenzymes are present in the liver, kidney, intestine, bone 
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and placenta. So, although the rise of concentrations serum ALP is a sensitive indicator of 
hepatobiliary disease, its low specificity for the liver disease is confusing. The Alkaline Phosphatase 
can then increase in case of liver disease, drugs hepatotoxic and in any form of obstruction of the 
biliary tract. In dogs, the total value of serum ALP contributes two isoenzymes liver, one produced 
by the liver (L-ALP) and one induced by corticosteroids (C48 ALP)40,41. Total plasma proteins are a 
collection of different molecular species; proteins, glycoproteins and lipoproteins. They originate 
mainly from the liver and they have nutritional function, buffer, coagulation and fibrinolysis, 
transport and colloid-osmotic pressure. The plasma concentration may be altered for both alterations 
that affect and alter protein metabolism and for alterations blood volume. The absolute value does 
not reflect the quantitative changes in the individual unit. The increase in total protein can be by 
dehydration, hemoconcentration, venous stasis during withdrawal; to increase gamma-globulins in 
certain situations of liver cirrhosis, autoimmune diseases or in the presence of abnormal proteins 
(monoclonal gammopathies or polygonal). The decrease in total protein can be by overhydration 
(reduction proportional of all fractions), to decreased synthesis for insufficient intake food 
(malabsorption for chronic liver diseases), for protein loss kidney, intestine, hemorrhage, malignancy 
or excessive catabolism endogenous protein.42-44  
 
 
AIM OF THE RESEARCH 
The aim of our work was to evaluate any liver damage in a heterogeneous population treated with 
two types of PN formulations for PPN. The named by us: “Low/Medium” and "High" amino acids 
formulas have the purpose to cover the caloric patients’ needs for the most part with the amino acids. 
The objective of our study was therefore to provide preliminary data that could indicate or suggest a 
greater use of the amino acid portion on the PN formulas, focusing our interest on one of the 
complications that may occur during the administration of this type of AN: the short and long-term 
liver damage44,47. Since any report from the literature concerning the administration of different  
amount of protein during nutritional therapy, nor amino acids effect on liver damage has been 
published, our study aims to evaluate the percentage of amino acid in PN solutions related to liver 
damage markers. The liver damage was monitored during the PPN administration through the 
quantification of three liver parameters, total protein (TP), Alanine Aminotransferase (ALT) and 
Alkaline Phosphatase (ALT). For the subjects with hepatic values in the physiological range the 
purpose was preserve them, while for those with liver values altered the aim was get as close as 
possible to the physiological ones. The results obtained could evaluate the safety could document an 
eventually not negative effect of the high amino acid formula on the liver damage. 
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purpose of the work is faithful to the clinical principle by decreasing the lipid amount in favor of  
amino acids, a fatty liver disease from lipid overload is disfavored. 
 
 
 
MATERIALS AND METHODS 
 
PATIENTS 
 
The study is based on a heterogeneous sample of 20 dogs, race, age, gender and disease, all of whom 
received PPN. All patients included in the study showed an inability to feed themselves or a 
gastrointestinal tract non-functionality. These characteristics have brought the dogs to present a state 
of undernourishment more or less marked, which is clinically manifested with a BCS less than 5 out 
of 9. Our subjects were all hospitalized for a time, by a minimum of 3 days, to a maximum of 32. 
During hospitalization, all subjects were treated with PPN via peripheral venous access for or a 
gastrointestinal tract functional disorders. All the patient showed a marked undernourishment, which 
was clinically manifested with a BCS less than 5 out of 9. During hospitalization, all subjects were 
treated with PPN via peripheral venous access for a variable time, from a minimum of 1 day to a 
maximum of 20. They were, however, subjected to different protocols regarding the percentage of 
amino acids administered with the PPN solution. The quote of amino acid ranged between 16-50%. 
For each dog enrolled in the study data related to signalament, clinical anamnesis, food intake, and 
the eventual therapeutic regimen were collected. General physical examination with particular 
attention to body weight, BCS and MCS presenting at the patient admission has been carried out. The 
nutritional status was considered good if the animal had less than three days of inadequate food intake 
and no signs of muscle loss. The nutritional status was considered discreet if the animal had more 
than three days of inadequate nutrient intake without muscle loss. The nutritional status was labeled 
poor if the animal had more than three days of inadequate nutrient intake with obvious generalized 
muscle mass loss121. In the clinical reports previous illnesses, biochemical exams before PN, 
estimated nutritional requirements, nutrient solutions used, changes in body weight during the 
administration of PN, complications encountered during the treatment, the results of cultures from 
the tip of the catheter, duration of PN and final conclusions were noted. The values of total protein 
(TP), alkaline phosphatase (ALP) and alanine aminotransferase (ALT) were obtained from blood 
biochemistry (Tab.4). 
The experimental design is a cross-sectional, prospective screening and case-control study, based on 
the following classification of the patient: Medium / Low Protein Level group were the subject who 
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were classify as good or discreet nutritional status, while the High Protein Level group were the dogs 
with a poor nutritional status were the animal had more than three days of inadequate nutrient intake 
with obvious loss generalized muscle mass. The dogs were randomized into two groups: GROUP 1 
(Medium / Low Protein Level group) composed by 11 subjects, receiving a normoproteic parenteral 
solution with a percentage of amino acids ≤ 25%, corresponding to an average of 1.9 to 2.2 g / kg / 
day of protein, GROUP 2 (High Protein Level group) consisting of 9 subjects, receiving a 
Hyperproteic parenteral solution with an amino acids amount > 25%, corresponding to an average of 
3.6 to 6 g / kg / day of protein. The protein portion varies not only from group 1 to group 2, but also 
within the same group according to the subject, while respecting the maximum limit of the interval 
to which belonged the subject. The total energy of parenteral solution, in both groups is calculated 
for cover the RER of the subject, so the number of calories provided by each component must always 
be equal to the daily energy requirements. 
 
 
 
DOG SEX BW 
KG 
AGE 
MONTH 
BCS  
3/9 
MCS 
3/5 
PATHOLOGY AA 
PN 
SOL.    
% 
Hospitalization 
lenght of stay        
 days 
Lenght 
of PN    
days 
1 M 6 192 4 3 Gastroenteritis, 
Paraprostatic cysts, 
Adrenal, Testicular and 
Liver nodule  
16 6 3 
2 F 15 24 4 3 Iatrogenic chlythorax 18 5 5 
3 FN 30 60 3 2 Volvulus of the small 
intestine 
18 4 3 
4 F 16 96 4 2 Nefrectomy and renal 
pelvic stones 
18 5 1 
5 M 17 156 3 3 Thorax foreign body  18 5 2 
6 M 6,7 156 3 3 Pancreatitis and 
adrenalectomy  
18 8 6 
7 FN 5,6 144 3 3 Surgical treatment of 
gunshot woud  
18 4 1 
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8 FN 40 42 4 3 Canine parvovirus 25 20 7 
9 M 6,3 10 3 2 Spontaneus hepatic rupture 18 8 5 
10 M 18 9 4 3  Splenectomy 33 8 3 
11 M 17 132 4 3 Idiopathic Megaesophagus 33 4 2 
12 M 32 60 2 3 Vascular ring anomaly, 
(retroesophageal left 
subclavian artery 
 
33 4 3 
13 M 7,2 4 4 3 Idiopathic Megaesophagus 23 7 6 
14 M 14 6 3 4 Canine parvovirus 25 7 6 
15 M 25 42 4 4 Enterectomy 
 
50 9 5 
16 M 6,3 96 2 2 Idiopathic Megaesophagus 50 32 20 
17 F 4,6 2 3 3 Gastroenteritis 50 3 2 
18 F 27 12 3 2 Gastroenteritis 
 
50 4 3 
19 F 3 4 4 3 Gastroenteritis 
 
50 7 3 
20 F 1 4 3 2 Canine parvovirus 50 4 4 
Table 4. Patients considered in our study 
 
 
 
PERIPHERAL VENOUS ACCESS PREPARATION  
The site from venous access was prepared in accordance with the surgical rules of asepsis and then 
fixed with a bandage. The PN venous catheter was used exclusively for the administration of 
parenteral solution. For intravenous fluid therapy and medications, a second venous access was used, 
while the blood samples were carried out in a third vein. 
 
PARENTERAL NUTRITION FORMULATION 
Each solution consists of an amino acid 8.5% solution (III Fremine), a 5% glucose solution (Glucose 
5%) and a 20% lipid solution (Intralipid), present in different concentration in a Three-in-one final 
solution. Freamine III amino acid contain 8.5% of L-essential free amino acids and non-essential. 
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It contains essential amino acids such as, L-Isoleucine, L-Leucine, L-Lysine Acetate, L-Methionine, 
L-Feninalanina, L-Treonina, L-tryptophan and L-Valine, the amino acids such as non-essential, L-
Alanine, L-Arginine, L-Histidine, L-Proline, L-Serine, L-Cysteine HCL. It has an osmolarity of 860 
mOsm /L and provides 0.34 kcal / ml.  
Parenteral solutions within the laboratories of Department of Veterinary Sciences for Health, Animal 
Production and Food Safety through the use of a laminar flow hood (TopSafe 1.2), from the single 
components to the three-in-one solution finished product. At 5% glucose solution were added first 
the solution amino acids followed by lipids. The solution, once ready for use was then stored at 4 C 
for a up to 24 hours. Each solution was calculated for one-time infusion of 12h.  
 
SCHEME FOR PER CALCULATION123 
 
1) the patient's daily calorie needs calculation 
RER = 70 x (BW kg) = kcal / day 
PER= 70% RER 
2) Calculation of the energy density of the solution 
Calories Sol.AA =% RER = kcal AA 
Sol.Glu Calories = kcal% RER = Glu 
Calories Sol.Lip =% RER = kcal Lip 
 
3) Calculation of the daily volume of each nutrient 
AA kcal x 0.34 kcal / ml = ml AA 
Glu kcal x 0.17 kcal / ml = ml Glu 
Lip kcal x 2 kcal / ml = ml Lip 
Tot Volume (ml): 24h = ml / h 
 
4) Ensure the osmolarity 
ml AA x mOsml / l AA 
Glu ml x mOsml / l Glu 
Lip ml x mOsml / l Lip 
Osmolarity Tot mOsml / l 
The osmolarity should be <650mOsml / PN in the central and 
> 1400 mOsml / l in that device. 
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PATIENT MONITORING  
Patients were monitored daily during the period of hospitalization. The daily evaluation included 
assessment of vital signs such status sensorium, hydration status, body temperature, heart and 
respiratory rate, mucous membrane color and capillary refill time (CRT), body weight, BCS and MCS 
in order to monitor their eventual change as an evaluation index of assisted nutrition. Increases in 
body weight in animals receiving an assisted nutrition intravenously for short periods, may actually 
reflect an increase of extracellular water within the tissues. Monitoring of the body weight is therefore 
a rudimentary method of measuring the effectiveness of same assisted nutrition. The laboratory tests 
were carried out according to the specific patient’s needs.  The blood was analyzed a minimum of 
three times during the study, according to the hospitalization length: 1) before starting the nutritional 
therapy, 2) during the therapy, and 3) at the end of the treatment. The first withdrawal allowed us to 
know the set (T1), then the influence of parenteral solution was detected with the second (T2) and 
the third (T3) blood tests. In our study, to perform liver response monitoring to PPN total protein 
(PT), alkaline phosphatase (ALP) and alanine Aminotransferase (ALT) were considered. Every 6/12 
hours the urine glucose was performed using strip test dipped in a urine sample, collected for 
spontaneous urination in a disposable container for the urine. 
 
MONITORING OF LIVER RESPONSE TO PPN   
Low specificity of the serum albumin as evidence of state of nutrition and liver damage, wasn’t 
examined in our study. The values we considered were the alanine aminotransferase (ALT), the 
alkaline phosphatase (ALP) and total protein (PT). Evaluation of serum concentrations of these 
hepatobiliary enzymes, is commonly used as a screening test to detect the presence of hepatobiliary 
disease. Although these enzymes are highly sensitive for the identification of hepatobiliary diseases, 
interpretation is hindered by their lack of specificity towards specific hepatobiliary disease.  
 
MONITORING FOR COMPLICATIONS 
Eventual complications evaluated were: mechanical, septic or metabolic. The mechanical 
complications included all the technical problems that interfere with administration assisted nutrition 
intravenously. Sepsis was defined by the presence of fever, depression, and leukocytosis with or 
without positive microbiological culture.  
The assessment of the presence of clinical complications was made following the American and the 
European Society of Parenteral and Enteral Nutrion, respectively ASPEN and 
ESPEN guidelines, where human patients are evaluated based on the presence or absence of: 
phlebitis, thrombus embolism syndrome post-PN lung, sepsis, systemic inflammatory response 
syndrome (SIRS), post-PN diarrhea, shock.  
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STATISTICAL ANALYSIS 
The collected data were analyzed by using SAS software. The distribution of the data allowed the use 
of different types of analysis: 
1) univariate analysis of variance (ANOVA) for each of the variables (“Gaussian" analysis) on the 
differences of values "post" and "pre" [SAS STAT, PROC GLM] {Pre, post}; the analysis comprises 
a single variable. The GLM studies the variance of a single variable and consider the measures of all 
subjects at various times without the repeated measurements, giving a variable response with normal 
distribution (Gaussian). 
2) Analysis of variance univariate repeated measures (Repeated measures ANOVA) for each of the 
variables (analysis: "Gaussian") [SAS STAT, PROC MIXED] {pre, post}; It includes a single 
variable in the study. The MIXED considers a single variable in the study and includes the measures 
repeated, giving a response variable with normal distribution (Gaussian). 
3) Analysis of variance univariate repeated measures (Repeated measures ANOVA) for each of the 
transformed variables in score, placing score 0 = no physiological value, score 1 = physiological 
value) (analysis "Binary") [SAS STAT, PROC GLIMMIX] {pre, post}; Consider the study 
a single variable. The GLIMMIX Procedures studying the variance of a single variable, including 
repeated measures of the subjects. The answer is a variable that has not normal distribution, so do not 
Gaussian but Binary. 
4) Analysis of variance multivariate repeated measures (Repeated measures MANOVA) on all 
variables simultaneously "as is" (Analysis "Gaussian") [SAS STAT, PROC MIXED] {pre, during, 
post}; It includes then more variables. 
The MIXED in Repeat Measures MANOVA considers more variables and includes in the study 
repeated measures, giving a variable response with normal distribution (Gaussian). Independent 
variables considered were: confounding variables: age and weight (continuous), BCS and MCS 
(Categorical); Variables of interest: % protein (categorical = "Cut", levels = [1,2]), time (Categorical 
= "Time", levels = [1 (2) 3]) Variable identifying the person: Dog (Categorical = "Dog"). The data 
were statistically significant with p-value< 0,05. 
 
 
RESULTS 
In this study 20 heterogeneous dogs for mixed race, gender, age and diseases, all in a state of 
malnutrition were treated with PPN. During the nutritional therapy, there weren’t any septic or 
metabolic complication PN-related. The only mechanical complication PN-related were little clot in 
the venous-catheter treat with NaCl 0,9% flushing within the venous line. The bacterial cultures 
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carried out in this study are not quantitative but qualitative. Only one animal, without clinical signs 
of sepsis, was found to be positive for bacterial growth (staphylococcus epidermis) suggesting 
bacterial colonization. In all other cases, the test was negative, thus excluding bacterial contamination 
of the catheter or the venous line. The results reported in the following tables were obtained by blood 
serum analysis. 
 
 
Table 5. Values of individual subjects of Total Protein in phases Pre, During and After (g/dl) 
 
The total protein values (Tab.5) were all lower than the maximum value of 7.5 g / dl. In 6 cases (Dog 
1,2,3,4,10,17) the final values, however, were lower than the minimum value of 5.4 g / dl. In these 
dogs, 5 had an increasing in PT values From PRE-to POST without reaching the physiological value. 
Among these, only one (Dog 17) had amino acids amount of > 25% in PN solution. 
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Table 6. Cases in which the final value of the Total Protein was less than the minimum value of 5.4 g / dl 
 
Table 7. ALT of individuals over time Pre, During and After, cut off for normal values is ALT<60 U/L. 
 
ALT values fall at the end of the therapy within the maximum range, all subjects had lower value 
than 60 U / L except for the Dogs 1, 4 and 10. Dog 1 and 4 started from very high initial values during 
the therapy declined while failing to re-enter the physiological maximum value. Dog 1 received a 
16% amino acids solution, Dog 4 an 18% one. Dog 10 ALT value increased, receiving a n 18% AA 
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solution. ALT levels greater than the maximum limits were obtained in only three subjects belonging 
to the group with parenteral nutrition < 25% (Tab.7). 
In all subjects in the group with amino acid solution > 25% ALT levels at the end of the treatment 
was <60 U / L. 
 
 
Table 8. Dogs with ALT values greater than the maximum parameters 
 
 
Table 9. ALP values for all subjects at the time Pre, During and Post, cut off for normal values is ALP <130 U/L.  
 
 
 
ALP value falling within the physiological range in 8 cases (Dog 1,2,6,7,9,11,14,17), while in 11  
patients (Dog 1,2,6,7,9,11,12,14,17,18,20) the value was diminished. In 6 animals (Dog 1,2,6,7,9,14) 
received a Medium / Low Protein Level Solution, while 5 (Dog 11,12,17,18,20) received a High 
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Protein Level Solution.  Only 3 presented in the POST phase a value within the maximum limit 
accepted, all however already they showed a physiological value in the PRE-phase. In 2 they had 
High Protein Level group solution and only one the Medium / Low Protein Level. 
 
 
Table 10. Cases in which ALP is decreased 
 
 
Table 11. Dogs in which the ALP is decreased while remaining beyond the threshold value from the PRE-to END. 
 
In 9 cases (Dog 3,4,5,8,10,13,15,16,19) the final value exceeds the initials. 6 belong from the  
Medium / Low Protein Level Solution group (Dog 3,4,5,8,1013), while 3 (Dog 15,16,19) from the 
High Protein Level Solution group. 5 subjects (Dog 3,13,15,16,19) remain inside the physiological 
range. 
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Table 12. Dogs in which the ALP end values increased  
 
Only in 8 cases (Dog 3,12,13,15,16,18,19,20) the ALP values are always within the maximum level 
of 130 U / L for all three phases of monitoring. Among these in 5 (15,16,18,19,20) had a protein 
content> 25% and only 3 (Dog 3,12,13) <25%. 
 
 
Table 13. Dogs in which the ALP has always remained <130 
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Chart 1. Graphical data of the Total proteins (a), ALT (b) and ALP (c) in each dog (full dot) from the patient number 1 to the patient 
number 20 in the different phases of the PPN: pre-PPN administration (yellow line), during PPN (blue line) and post-PPN (violet 
line).  
 
 
 
 
 
 
 
 
 
g/dl U/L 
U/L 
dogs 
dogs 
dogs 
a 
c 
b 
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STATISTICAL ANALYSIS 
 
 
 
 
 
 
 
 
Table 14. Blood exams results expressed in mean, standard deviation, minimum and maximum values. Medium / Low Protein Level 
group (cut 1), High Protein Level group (cut 2); pre-PPN administration (time 1), during PPN (time 2), post-PPN (time 3); number of 
subjects/observation (N Obs). Variable/label: aminotransferase (alt), the alkaline phosphatase (alp) and total protein (prot).  
  
 
 
 
All the statistical test differences (observed probability (p value) at the alpha level = 0.05) in the 
analysis objective. Other none statistical variables significance, such as age, weight, BCS and MCS 
were found. 
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DISCUSSION 
 
The appropriate protein-calorie determination in the canine patient during parenteral nutrition is 
fundamental for their clinical management. This allows for early recovery minimizing protein 
breakdown, without overloading liver and kidneys. The knowledge of the PN impact and the role of 
the amino acid on liver function (based on liver damage) allows the clinician to understand how these 
compounds may be employed as nutritional support without damaging the organs as liver or kidney. 
Studies relating to the parenteral nutrition refer to the use of parenteral solution which satisfy the 
minimum requirement needed in a dog. In spite of some clinical study showing the effects of PN on 
liver function in human patient with liver disease are present in the literature45, there are no studies 
evaluating the use a high-protein parenteral solution (> 25%) and its effect on liver function in clinical 
veterinary patients. Effect of over amount of selected PN solutes on dogs were performed by Zentek 
et al that evaluated the effects of two parenteral solutions on liver function, one was hyperlipidic 
while, the other, had a hyperglucidic content. Complications occurred in dogs were 
hypertriglyceridemia with fever and nausea for the hyperlipidic one, and hyperglycemia necessitating 
insulin therapy for the hyperglucidic solution46. Our study was directed to evaluate how different 
amounts of amino acid could interfere with liver metabolism and, on the other hand, could substitute 
lipids and/or carbohydrates as energy source during PN in undernourished dogs. Starting from these 
premises and facing the scarcity of references in literature we clinical and hematological values.  The 
study conducted did not bear statistically significant differences in liver function tests: ALT, ALP 
and PT between the two groups of animals that were administered using the two parenteral solutions 
denominated "Low-Medium" and "High" amino acids percentage. We were able to vary the amount 
of protein within a range so wide because no indication in literature was present about the PRC in a 
starving dog in the course of nutritional therapy, including PN. Lacking any kind of reference, we did 
change the RPC, starting from the values shown for a healthy dog, then we edited it basing on the 
protein daily requirement of the subjects, according to the metabolic and clinical response of the 
patient as a function of the results obtained up to that moment. We increased the percentage of amino 
acid to verify the liver response with the increase of the protein and look for an eventual correlation 
between high amino acid concentration and liver function, and to evaluate better results than in the 
first obtained. In group 1 (cut 1 the proportion of the three components the solution is very similar, 
so the energy comes from the three PN components equally. In group 2 with high-protein solution on 
the other hand most of the energy is provided by the amino acid level. To understand correctly the 
data, before analyzing other parameters first we evaluated the evolution of ALT, ALP and total 
protein in all subjects, in times T1 (Pre), T2 (During) and T3 (Post), always in reference to the group 
they belong to, Cut (1 and 2) (Tab.14). Subsequently in the study other variables, such as age, weight, 
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BCS and MCS were evaluated. Total protein increases in all subjects, while remaining within the 
limit accepted. The parameter hasn’t exceeded the maximum value, regardless the percentage of 
amino acid administered. Only in one case the value is decreased for a subject belongs to the group 
1, while in 5 cases the value has remained below the minimum accepted limit. This occurred mainly 
in group 1; while only a subject belonging to the group 2 has a value less than 5.3 g / dl, which would 
seem to indicate that the high amino acidic solution gives a better response. The ALT in the high-
protein solution induced an improvement of the enzyme concentrations within physiological range. 
Only three subjects, in the POST, presented greater values compare to the maximum limit accepted, 
and all belong to the group 1, while two subjects have a decreased parameter. Only in one case 
belonging to the group 1, the value in the POST phase was greater than the phase PRE; the dog 
however presented hepatic rupture, so its increase could also be due to the disease. The same subject 
has a very high ALP that, also in this case it has gone to increase from stage PRE to POST. It would 
appear that the high protein solution had a better impact on ALT, although both solutions showed an 
improvement with a lowering of all the parameters evaluated in 19 out of 20 dogs.  
The comparison between the PRE and POST liver values in relation to the amino acid percentage in 
the PN solution, did not suggest any statistically significant difference. The results are always greater 
than the p-value (α = 0.05) in GLM, which consider the variables without the repeated measures 
obtaining a linear response. Both in MIXED studies and in GLIMMIX which instead it takes into 
consideration also the repeated values had a p-value> 0,05. This indicates that no group prevails over 
the other. In the GLM study, in addition to the statistical significance, the average between the POST 
and PRE-difference of the ALT, ALP and PROT TOT values in the two groups was calculated. It is 
therefore possible to claim that the two solutions have given the same results by affecting liver in a 
nearly identical way and that the two solutions gave the same results, influencing the liver function 
in an almost identical manner. No differences were found in any statistical procedure applied to our 
study. While it is recognized that liver test abnormalities occur during TPN, the question is whether 
TPN is associated with chronic liver disease. Total parenteral nutrition is considered to be an absolute 
risk factor for the development of biliary sludge and gallstones, often associated with hepatic 
steatosis. The incidence of total parenteral nutrition-related hepatobiliary complications has been 
reported to be very high, ranging from 20 to 75% in humans. All these hepatobiliary complications 
are more likely to occur after longterm total parenteral nutrition. End-stage liver disease has been 
described in approximately 15–20% of patients receiving prolonged total parenteral nutrition. The 
hepatic diseases referenced by the different studies in medicine attribute the liver damage and an its 
altered functionality during long-term TPN on the presence of an excessive lipid concentration or an 
excessive lipid peroxidation in the PN formula. The references in the literature therefore focus on the 
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full evaluation of the formulations with a higher content of glucose or lipids41,44,47.  Chandler et al. 
determined the effect of PPN on nitrogen balance as an indicator of the effect on protein sparing, 
serum folate concentrations and serum insulin-like growth factor-I (IGF-I) concentrations in fasting 
dogs48. Hata et al. studied the effects of an amino acid mixture used for TPN in pediatrics founding 
that their amino acid solution for pediatrics has no significant effect on LFTs in neonates, even when 
high doses of amino acids (3.5g/ kg per day) were infused49. Olan et al. described the use of 
ProcalAmine as a source of parenteral nutrition in hospitalized dogs and its possible complications 
connecting the same idea of our purpose to evaluate a amino acids dosage for PN needs lower than 
us. Few clinical studies have examined the effects of specific amino acid mixtures on TPN-associated 
cholestasis. In one such study, Vileisis et al. reported the effect in humans of the amino acid intake 
in a high amino acid group (3.6g/kg per day) and a low amino acid group (2.3 g/kg per day)50. 
Although the incidence of cholestatic jaundice was almost identical in the two groups, the onset of 
cholestasis from the beginning of TPN occurred sooner and the peak value of direct bilirubin was 
higher in the high amino acid group. In experimental animal studies, Merritt et al.  observed a direct 
cholestatic effect of tryptophan in suckling rat pups, and Belli et al. showed decreased bile flow in 
rats with amino acid imbalance51,52.  
In all the studies mentioned above the final discussion is directed to the future use of the amino acids 
solution as the only energy and structural nutritional compound during PN. Through the results of 
these studies in was found that all the hepatic marker was improving the liver state of function and 
damage.   
As already discussed, a generous protein intake is usually recommended for dogs with cachexia or 
poor nutritional status. The goal is to support anabolic processes to the greatest degree possible, 
preventing protein-calorie malnutrition. However, providing dietary protein at levels above the 
animal’s needs is expensive and provides little benefit. Protein requirements are dictated by 
requirements for essential amino acids that cannot be synthesized endogenously. Many studies in 
numerous species indicate that these requirements are increased during critical illness regardless of 
etiology8. 
There are several limitations in this study to be considered. One is the small number of dogs in the 
study, which may have prevented detection of significant effects by other variables. To our 
knowledge, this is the first study to indicate the probable clinical advantages of amino acidic nutrition 
in dogs with poor nutritional performance. This preliminary data could be a first step for a clinical 
research focused on liver activity in a much larger trial for the veterinary practice and for translational 
medicine with the association of the dog as a model for infant patients.   
 46 
The choice of only three blood makers for hepatic damage was done following the dictates of the 
most common and easily performed indices of liver suffering. Moreover, it is known as ALP, ALT 
and total proteins can be early markers of liver damage (from a few days to 3 weeks we can highlight 
any damage to the liver). In particular, the choice fell on the use of ALT as marker parenchymal 
marker and ALP as a biliary damage signal47.  
 
 
CONCLUSION 
 
This evaluates the effects of two parenteral solutions enriched with different amino acid 
concentrations, on hepatic function in the critical canine patients. There are no studies in the 
veterinary literature that deepen the theme of the amino acid quota, which studies its effects on liver 
function. Up to now, texts and literature have always recommended a low-medium amino acids 
solution. The use of a high amino acids solution would reduce the lipid and glucidic fractions, thus 
reducing the risk. With this part of my doctoral project, the metabolic effects of a high amino acids 
solution on liver function compared to a low-medium amino acids solution have been evaluated. The 
aim was to verify a correlation between increased amino acids content and an increase in secondary 
complications with repercussions such as liver damage. Although data came from a  limited sample 
of subjects, the results obtained has to be considered interesting. We started by giving the first group 
a standard, low-medium amino acids parenteral solution, then passing on to a high amino acids 
solution, departing from what recommended in the literature. We have investigated the increase of 
protein alone at the expense of the other two fractions. The results obtained show that there is no 
statistically and clinically significant difference between the two protocols. It would therefore seem 
that the administration of a low-medium amino acids parenteral solution affects liver function in the 
same way as a high amino acids solution. It would be interesting to continue to deepen the amino acid 
profile of parenteral nutrition not only from the quantitative point of view as a whole but also from a 
qualitative point of view, considering the individual amino acids and their role within canine protein 
metabolism. In fact, in this study, the amount of Freamine III in the solution was increased, thus 
increasing the amount of all the amino acids administered113. On the other hand, acting on the 
qualitative point of view, we may only vary the amino acid concentrations of our interest. In this way, 
the overall amino acid fraction would not increase much but would only interfere with the metabolic 
pathways of our interest. For example, integration of the solution with BCAA has already been 
partially tested in some preliminary studies, especially on patients affected by liver pathologies in 
which contradictory results have so far been, but this would be a field to be investigated.53  
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It would be desirable to broaden the sample of homogeneous subjects in order to obtain statistically 
more robust data and to evaluate the evolution over time of multiple parameters not only of liver 
function but also of renal function. In order to evaluate the effect of the solution on the whole 
organism. It would be also interesting to study the impact of parenteral nutrition in a homogeneous 
group of subjects on the basis of primary pathology due to malnutrition, in order to study whether 
cases with the same pathology respond similarly to the same protocol or whether there are specific 
variables subjects that influence the treatment response. The aim would be to identify a universal 
parenteral nutrition protocol based on the pathology or, if this is not possible, to identify which 
subjective variables cause a different response between the cases. 
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4.Chapter: Use of 2D and 3D rabbit 
hepatocyte cultures to investigate Branched-
Chain Amino Acid effects in liver 
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INTRODUCTION 
Hepatocyte culture and isolation started during the end of 1960s1, where the isolation of the 
hepatocyte was carry out by simple incubation of the whole liver with enzyme digestion using 
collagenase and hyaluronidase followed by mechanical treatment. Hepatocytes serve as an in-vitro 
model for toxicological experiments and pharmacological testing2,3,4 or as the basis for regenerative 
liver medicine5. 
Moreover, the present and future prospectives for hepatocyte in vitro culture are the application in 
clinical cells transplantation6,7 using decellularized matrices10,11 or 3D-printed scaffolds 
recellularized with primary hepatocytes as completely bioengineered organs12,13. These therapeutic 
options are still experimental and in vitro liver grow is one of the main field in regenerative medicine.  
Liver transplantation seems to be only successful treatment for patient with end stage liver pathology.  
Global liver cirrhosis deaths increase from around 676,000 in 1980 to over 1 million in 2010, about 
2% of the global total11.  
Treatment for end-stage organ failure is restricted by the critical shortage of donor organs with the 
organ waiting list currently at 123 000 requests, a number that far exceeds the supply of available 
organs and that continues to grow by 5% each year. This situation has been the major driving force 
behind the rise of whole-organ engineering that aims to build transplantable organ substitutes to 
address the void in organ replacement therapies.  
One limiting aspect in wholeliver engineering is the lack of a reliable cell source for primary adult 
hepatocytes. Pluripotent stem cells have the potential to generate an abundant supply of functional 
hepatocytes for use in cell-based therapies12.  
The main problem of the organs transplantation is their primary source. For these purpose, a novel 
technique as split liver transplants, living-related partial donor procedures and the increasing use of 
“marginal” organs such as older donors, steatotic livers, non-heart-beating donors, donors with viral 
hepatitis, and donors with non-metastatic malignancy.  
To date, the availability of the liver grafts is no sufficient to meet their increasing demand. 
Some studies have find that the decellularization of the liver parenchima can produce a liver organoids 
implantable in the future13.  
The liver is maily composed by two type of epithelial cells called hepatocytes and colangiocytes. 
Both cells synthesize essential serum proteins, control metabolism, and detoxify a wide variety of 
endogenous and exogenous molecules14 LIVER15 (Fig.1).  
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Figure.1 Liver lobular organization. Anatomical localization of the hepatic progenitors cells (HPC). 
 
Despite their considerable replication capacity in vivo, hepatocytes present a limitation in some in 
vitro culture for their expansion resistence16. In recents study there are new culture strategy developed 
to maintain longer viability and vitality of this parenchimal cells. Culture system that allows the long-
term expansion (>1 year) of single mouse adult liver17, remaining committed to their tissue of origin.  
First of all, before introducing the in vitro studies to better understand the mechanism of liver 
rigeneration and approach the experimental design of my PhD thesis, I start from an anatomy and 
embriology background of the liver.  
During the embryo phase, the first anlage of the bile ducts and the liver is the hepatic diverticulum or 
liver bud. The extrahepatic biliary tree develops through lengthening of the caudal part of the hepatic 
diverticulum. This structure is patent from the beginning and remains patent and in continuity with 
the developing liver at all stages. The hepatic duct develops from the cranial part of the hepatic 
diverticulum. The distal portions of the right and left hepatic ducts develop from the extrahepatic 
ducts. The proximal portions of the main hilar ducts derive from the first intrahepatic ductal plates. 
The extrahepatic bile ducts and the developing intrahepatic biliary tree maintain luminal continuity 
from the very start of organogenesis throughout further development, contradicting a previous study 
in the mouse suggesting that the extrahepatic bile duct system develops independently from the 
intrahepatic biliary tree and that the systems are 
 51 
initially discontinuous but join up later. The normal development of intrahepatic bile ducts requires 
finely timed and precisely tuned epithelial–mesenchymal interactions, which proceed from the hilum 
of the liver toward its periphery along the branches of the developing portal vein18. The vascular 
architecture of the liver is established at the end of a complex embryological history, is in contact 
with two major venous systems of the fetal circulation: the vitelline veins and the umbilical veins. 
The portal vein is formed from several distinct segments of the vitelline veins; the portal sinus, 
deriving from the subhepatic intervitelline anastomosis, connects the umbilical vein, which is the 
predominant vessel of the fetal liver, to the portal system; the ductus venosus connects the portal 
sinus to the vena cava inferior. At birth, the umbilical vein and the ductus venosus collapse; the portal 
vein becomes the only afferent vein of the liver. Hepatic sinusoids progressively acquire their 
distinctive structural and functional characters, through a multistage process19.  
After the embriological developement, in the adult rabbit, we can find all the liver gland formed under 
different projection areas. The rabbit has 12 pairs of ribs, the last three are short and cartilage-free. 
The liver occupies the xifoid region, on a triangular area, whose summit is covered by the xifoids 
process of the sternum and whose base protrudes obliquely from the ventral end of the ninth 
(accasionally tenth) left to the seventh (rarely eighth) right coast. The right liver comes under the 
penultimate coast, rarely under the last, only with the process caudate. The right lobe has reduced 
projection area compare to the left side lobe that is projected to the dorsal end of the tenth coast. The 
medial lobe reaches the right lobe near the right costal arch. The gallbladder is located deep and not 
far from the medial plane, a level of the ventral end of the sixth space intercostal. Vascularization of 
the lumbar region: 
The celiac trunk is born under the caudal end of the last thoracic vertebra. The mesenteric cranial 
artery begins a level of the intervertebral disc of the first two vertebrae lumbar. 
The caudal mesenteric artery is much thinner than the mesenteric cranial artery and originates under 
the sixth vertebra lumbar. 
The aorta ends at the level of the seventh lumbar vertebrae, bifurcating in the two iliac arteries 
common. The rabbit liver weighs in the 80 to 120g average.  The liver margins give attack to the 
peritoneal coronary ligament and prolonged in the addominal cavity. 
The liver is divided into a left lateral lobe, left medial lobe, right foot 
The quadrate lobe is subdivided and it is narrow and not voluminous. The caudate lobe, also, is 
subdivided by the incision of the caudal vena cava in a caudate process (very developed) and in a 
papillary process20.  
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During development or a pathological insult to the liver has a unique regenerative capacity of its kind. 
The repair-development process can be associated and equated although the literature does not 
differentiate clearly still embryonic cells from progenitor cells are still not well defined by modern. 
 
LIVER REGENERATION 
 
The wide array of functions performed by liver towards the rest of the body has been safeguarded by 
evolutionary events which imparted to liver a phenomenal capacity to regenerate. This process allows 
liver to recover lost mass without jeopardizing viability of the entire organism. The phenomenon of 
liver regeneration following loss of liver mass is seen in all vertebrate organisms, from humans to 
fish. It is also triggered when livers from small animals (e.g., dogs) are transplanted to large recipients 
of the same species. It has been recorded and mythologized in ancient times from the myth of 
Prometheus and libraries of clay tables picturing scarred livers of sacrificial animals, used to foretell 
the future in ancient Babylon and Rome21.  
Loss of liver mass can be induced by administering hepatotoxic chemicals (e.g., carbon tetrachloride) 
or by a surgical procedure which removes 2/3 of the liver mass in rodents (rats and mice), a technique 
known as 2/3 partial hepatectomy (PHx)22. 
These procedures are followed by an inflammatory response which removes tissue debris, followed 
by the regenerative response.  A 2/3 PHx leaves a residual leading to 60% of hepatocytes and they 
undergo one mithosis in the average of 24h and 36h for rat and mouse respectively.  
Only a small percentage of cells enter in G0, associated to a wave of apoptosis that seems to be the 
own liver control to avoid an over-shooting of the regenerative response23. The proliferation of 
hepatocytes advances from periportal to pericentral areas of the lobule, as a wave of mitoses24 the last 
cells that undergo replication are the pericentral veins hepatocytes25. In term of proliferation time, fist 
cells are the hepatocyte on days 2-3 than the endothelial cells occur on 4-5 days after Phx. Stellate 
cells are cells of myofibroblastic origin, surrounding hepatocytes, located under the sinusoidal cells, 
producing extracellular matrix and several cytokines including HGF, and having a gene expression 
pattern substantially similar to the astrocytes of the brain26. The normal weight of he liver is 
reestablished within 5-15 days in human and animals. The entire liver mass is restored thanks to the 
manys mature adult hepatocytes instead of selective subpopulation of stem cells. To approach the 
entire signaling pathways triggered during liver regeneration strongly we have to think about those 
mechanism of wound healing, seen in other tissues. The main differencies are concernig the whole 
organ, thus the restore of a single lobe provoke changes in trophysm and metabolysm in the entire 
gland. Even though there is no damage to the residual tissue, there are big changes in hepatic blood 
flow patterns. The hemodynamic alterations after PHx induce the arterial component of the blood 
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supply per unit of liver tissue does not change after 2/3 PHx; the portal contribution per unit tissue, 
however, triples. Portal vein continues to carry the entire outflow from intestine, spleen and pancreas. 
The entire flow now needs to traverse through a capillary bed whose cross-section is mathematically 
down to 1/3 of the original. The hepatic capillaries have fenestrated endothelial cells which bring 
direct access of plasma through the endothelial cells to the hepatocytes. If these changes ar not present 
there is a deficiency on the activation of the HGF27 and an alteration of the oxygen concentration. 
Portal vein carry much lower oxygen amount compare to hepatic artery.  The relative increase in 
portal blood per unit liver tissue after PHx should result in decreased oxygen pressure in the 
circulating blood, perhaps triggering a hypoxic response. The tripling of the portal vein contribution 
should also cause a mathematical tripling in the availability per hepatocyte of growth factors and 
cytokines derived from intestine and pancreas. All aspects of liver regeneration, the importance of 
the hemodynamic events and the change of relative nutrients supplied as the correct level of the grow 
factors like epidermal growth factor (EGF) in in the portal blood.  
One of the earliest observed biochemical changes is increase in activity of urokinase plasminogen 
activator (uPA) (Fig. 2).   
 
 
Figure. 2 Chronology during early stage of liver regeneration. 
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There is an increase in uPA activity throughout the entire liver starting as early as 5 min after PHx29. 
The relationship between increase in uPA and the hemodynamic changes seem to be an increase of 
uPA in several cell types including endothelial cells following mechanical stress associated with 
increased turbulent flow30. Thus, alterations of vascular flow patterns alone can trigger some of the 
early events. Increase in uPA activity is accompanied by activation of plasminogen to plasmin (within 
10 min) and appearance of fibrinogen degradation products31. Urokinase is known to activate matrix 
remodeling, seen in most tissues during wound healing and also in liver regeneration. Many proteins 
of the extracellular matrix are subject to turnover. The activation of metalloproteinase 9 (MMP9) is 
seen at 30 minutes and further into the first 24-48 h afer PHx32. Wound healing and tumor biology 
have shown that matrix remodeling causes signaling though integrins and is associated with release 
of locally bound growth factors and peptides that have signaling capabilities. While there is not much 
proteinaceous matrix in the liver visible under the microscope, there is a great abundance of heavily 
glycosylated proteins in the pericellular space surrounding hepatocytes. Glycosaminoglycans are very 
abundant in liver and heparin, a shorter derivative, owes its name to liver (‘‘hepar’’). Several 
mechanisms are moving the repopulation and restituzion ad intergreum thanks to the extracellular 
matrix, where the metalloproteinase and their inibitors are comunicating34 and binding many growth 
factors. The most rappresentative of the grow factos is the hepatic grow factors35 (HGF). 
Pre-existing stores of inactive and active HGF rapidly diminish with the first 3 h after PHX, as HGF 
rises in the plasma by 10- to 20-fold36. This HGF is bound to hepatic biomatrix, that relase activated 
uPA that is a highly homologous to HGF, HGF and plasminogen have the same consensus sequence 
(RVV) at their activation site, so HGF is available locally and in the circulation. Hepatocytes culture 
suggest that TNF may play a role in this process by inducing expression of MMP9 by hepatocytes37. 
Hyaluronic acid (a major component of hepatic biomatrix) and TGFß1 are release locally and in the 
sistemic circulation TGFß1is a known hepatocyte mito-inhibitor38. When the receptor TGFß1R is 
rendered inactive in normal, non-regenerating liver by injecting dominant negative DNA constructs, 
there is a noticeable increase in DNA synthesis of hepatocytes39. This suggests that TGFb1 exercises 
a competing tonic effect against opposing effects of matrix bound growth factors, keeping 
hepatocytes of the normal liver in a state of quiescence.  The role of biomatrix on the cell expasion is 
achived by causing release (local and in the circulation) and activation of HGF while releasing TGFb1 
massively in the circulation, where TGFb1 is bound and inactivated by alpha-2-macroglobulin40. 
Same procesed happen with the relase of EGFR, bounded by the EGF produced in the duodenum by 
exocrine glands, and cMet41. The similar time kinetics of activation of the HGF and EGF receptors 
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suggest that EGF, now targeting fewer hepatocytes, has an enhanced effect; or that the EGFR 
becomes more sensitive to EGF. Independent work suggests that the latter may be true. 
Norepinephrine, which also increases in the peripheral circulation, is known to enhance the effect of 
HGF and EGF receptors in hepatocyte cultures through the alpha-1 adrenergic receptor. Blockade of 
the alpha- 1 receptor suppresses liver regeneration42. Other studies have also shown that there is a 
cross-talk between Met and EGFR and it is possible that activation of Met enhances activation of 
EGFR43. The events occurring in the early period of 0–5 h after PHx have often been called 
‘‘priming’’44. The term is a useful one, in that it denotes not only events associated for preparation 
for entry into the cell cycle, but also events and strategies of hepatocytes aimed at modifying patterns 
of gene expression so that they continue to deliver their homeostatic functions. The terminogy of 
‘‘priming,’’ has also been used to denote a time in which events occurring are induced only by 
cytokines, with events induced by growth factors occurring after the cytokine-mediated events. The 
findings described above, however, clearly denote that there is no demarcation point that can be 
ascribed to separate events induced only by cytokines or only by growth factors.  Quiescent 
hepatocytes in normal liver express a variety of growth factor receptors. These include receptors for 
PDGF, VEGF, fibroblast growth factor receptors, c-Kit. Primary culture however has shown that 
despite the expression of many mitogenic receptors, the only mitogens for hepatocytes in chemically 
defined serum-free media are HGF and ligands of the EGFR (EGF, TGFalpha, Amphiregulin, HB-
EGF, etc). These ligands are direct mitogens, in that they induce a strong mitogenic response in 
hepatocytes in primary culture and clonal expansion of their population47. HGF, EGF, and TGFalpha 
also induce hepatocyte proliferation and liver enlargement when injected alone into intact normal 
mice and rats48. In addition to these proteins, however, there are other substances which, although not 
directly mitogenic to hepatocytes, enhance the effect of the direct mitogens. Despite to the entire 
signaling pathway originated throw the extracellular matrix and the different cells type, the 
consecutive mechanis to evaluate is base on the role of the adult hepatocyte in relation to the hepatic 
progenitor’s cells (HPCs).  HPCs are present in adult liver, in small numbers in the Canal of Hering, 
the smallest ramifications of the intrahepatic biliary tree49. Extrahepatic peribiliary glands is 
described as the prime location for HPCs50,51. Some publications even speculate on a hematopoietic 
origin of HPCs, which is also highly debated. Different HPC-markers, such as keratin albumin, 
Alpha-Feto protein and HNF4α are collected in some studies52. Others marker as Keratin (K) 7 and 
K19, CD133 and EpCAM are shared with cholangiocytes, hematopoietic stem cells and embryonic 
stem cells. HPCs are epithelial cells that can display mesenchymal characteristics, depending on their 
activation status52. Recent studies have also focused on pro-regenerative effects of components of 
complement, bile acids, and serotonin, substances not known or tested to have direct or indirect 
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mitogenic effects. Some of the above signaling molecules were implicated based on decreased 
regeneration when their signaling is eliminated.  
One of the molucules recently studied are the branched chain amino acids (BCAAs), leucine, 
isoleucine and valine (Fig.3). Recent studies have revealed the functions of these BCAAs, and they 
have been administered for the treatment of advanced liver diseases. In mice, BCAA-rich diets have 
shown to up-regulate the expression of peroxisome proliferator-activated receptor (PPAR) γ 
coactivator-1α (PGC-1α), a master regulator of mitochondrial biogenesis and the defense system 
against reactive oxygen species (ROS), and of sirtuin-1, a member of the sirtuin family linked to life 
span extension, enhanced mitochondrial biogenesis, and decreased ROS production, leading to the 
prolongation of the lifespan of male mice54. BCAAs have also been shown to induce the activation 
of genes involved in antioxidant defenses and inhibition of ROS production, as well as to induce the 
hepatic expression of mRNA encoding 8-oxyoguanine DNA glycosilase 1, an enzyme involved in 
repair of oxidative DNA damage, in a rat model of liver injury, indicating that BCAAs are involved 
in the induction of antioxidant DNA repair55. In various cell lines, BCAAs, especially leucine, have 
been shown to activate the mammalian target of rapamycin (mTOR) signals, stimulating the synthesis 
of proteins, including albumin56.  BCAA activation of mTORC1 has also been associated with cell 
growth57 and PGC-1α- mediated mitochondrial gene expression57. BCAAs have been shown to up-
regulate PPAR-γ and uncouple (UCP) 2, reducing triglyceride concentrations in mouse livers58. These 
findings suggest that BCAAs may have a therapeutic effect on metabolic disorders and/or obesity. 
Apoptosis and regeneration of hepatocytes BCAA supplementation was shown to delay the 
progression of CCl4-induced chronic liver injury in a rat model by reducing hepatic apoptosis59.  
 On the other hand, BCAAs promoted hepatocyte regeneration in a rat model of hepatectomy60. 
Moreover, BCAAs were reported to stimulate the production of hepatocyte growth factor61. Taken 
together, these findings indicate that supplementation with BCAAs, by reducing hepatocyte apoptosis 
and promoting liver regeneration, may result in rapid recovery from liver injury. BCAAs activate 
mTOR and subsequently increase the production of eukaryotic initiation factor 4E-binding protein-1 
and ribosomal protein S6 kinase, which upregulate the synthesis of albumin62,63. Furthermore, leucine 
stimulates the nuclear importation of polypyrimidinetract polypyrimidinetract- binding protein, 
which binds to albumin mRNA and increases its translation64. 
 BCAAs were shown to improve homeostasis model assessment scores for insulin resistance 
(HOMA-IR) and beta cell function (HOMA-%B) in patients with chronic liver disease, indicating 
that BCAAs can ameliorate insulin resistance. In mice lacking the gene encoding mitochondrial 
BCAA aminotransferase, an enzyme that catalyzes BCAAs, serum BCAA concentrations were 
elevated. In those mice, fasting blood glucose and insulin concentrations were decreased and HOMA-
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IR was significantly lower than in wild-type mice65. Furthermore, administration of leucine or 
isoleucine improved insulin sensitivity in mice with high-fat diets66.  BCAAs were also shown to 
temporarily increase plasma insulin concentrations in healthy young men, although plasma glucose 
concentrations were not altered67. 
The BCAAs play an important role also on the cancer biology, some culture system analyzed their 
effects on the hepatic cellular carcinoma (HCC) lines increasing their concentration in culture 
medium.  BCAAs were found to accelerate insulin-induced vascular endothelial growth factor 
(VEGF) mRNA degradation at the post transcriptional level, downregulating VEGF expression 
during the development of HCCs68. BCAAs were also shown to induce apoptosis of liver cancer cell 
lines by inhibiting insulin-induced PI3K/Akt and NFκB pathways through mTORC1- and mTORC2- 
dependent mechanisms69. Moreover, BCAAs may inhibit obesity-related hepatocarcinogenesis by 
suppressing the stimulatory effect of visfatin, an adipokine with a critical role in HCC proliferation70-
72. Insulin was found to induce cell proliferation through activation of the mitogen-activated protein 
kinase pathway73, and BCAAs inhibit insulin signals by suppressing the expression of insulin-like 
growth factor74. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 58 
 
 
Fig.3 
Pathway of branched chain amino acid catabolism. BCAA are catabolized to acetyl-CoA and/or succinate-CoA and subsequently 
enter the TCA cycle. The main steps of the catabolic reactions (transamination by BCAT and decarboxylation by BCKD) are shown. 
With the help of BCAT, BCAA are catabolized into branched-chain α-ketoacids which are subsequently decarboxylated by BCKD. 
Finally, all the BCAA metabolites are catabolized by a series of enzyme reactions to final products and enter the TCA cycle74. 
 
AIM OF THE RESEARCH 
 
Aim of the present study was to determine how BCAAs preserve liver functions and cells 
proliferation in a novel 3D model, using a decellularized liver, as a most realible and faithful 
reproduction of the natural mechanisms in the liver compare with the standard 2D monolayer cell 
culture. Futhermore, in order to address wich cell type proliferation is present in relation of the 
BCAAs concentration we want to detect the mRNA expression in the liver organoid during three-
times culture on the 7,14, 21 days. All the data and results collected wants to validate the hypothesis 
of positive BCAAs effects on normal or pathologic liver described in the recent in vitro studies. The 
main scope is to sustain the proliferative BCAAs effect on the HPCs like it happen in the liver bug 
during the embriogenesis75, explaining and confirming the three amino acids active role on the hepatic 
regeneration also in the adult liver.          
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MATERIAL AND METHODS  
 
ANIMALS AND LIVER HARVESTED  
Two adult female New England White Rabbit 3 kg not eviscerated carcasses from a local 
slaughterhouse were collected, carrying it with a certified ice container. Before the incision, the 
abdominal wall was treated with topical chlorhexidine skindisinfectant with alternating chlorhexidine 
soaked gauze and dry gauze. Ventral mild line laparotomy extending from the pubis to the xyphoid 
combinewith a roof top incision using the #3 handle with #15 blade wasb perrformed. 
We Dissected the falciform ligament with Metzenbaum scissor. A wet gauze bandage to hold the 
medial and left liver lobes cranially under the dome of the diaphragm was used. The upper omental 
liver lobe was mobilized than the stomach to the left was move. The stomach with a clamp was fixed 
and the minor omentum with Metzenbaum scissor and DeBakey forceps was dissect. The bile duct 
was detatched from the adipose and pancreatic tissue. The bile duct was cut 1.5 cm from the 
bifurcation. The portal vein tissue and the common hepatic artery were dissected from the 
surrounding tissue. The hepatic artery was tied up twice with silk 3-0. The inferior vena cava between 
the right kidney and the right lateral liver lobe were circumscribed. The vein was dissected from the 
retroperitoneal space and we injected 1,000 I.E. heparin in 1 ml 0,9 % saline solution into the inferior 
vena cava. We retracted the cannula and close the incision with a cotton pad than stoped for 1-2 min 
for the effect of heparin. Then we cannulated the portal vein with a Sheath introducer 8,5 Fr and a 
vein pick catheter introducer cutting the vein near the knots with a Potts scissor. After fixed the 
decellularization cannula with 3-0 silk sutures, we Injected a total of 2 mL heparin sodium (100 
U/mL) through the vein to prevent coagulation. Then, infrahepatic inferior vena cava was transected 
to allow the outflow of the perfusate. Perfuse a total of 50 mL phosphate-buffered saline (PBS) slowly 
through the PV clear blood from the liver. The whole liver was isolate and transfer to the 
decellularization circuit (Fig.4). To collect the liver for the hepatocytes isolation protocol we cut the 
organ with Mayo scissor at the level of the grove liver for vena cava and its peritoneal ligaments. At 
the end, we transfer the whole liver to a 100 mm Petri dish. 
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Fig.4 
Schematics of the dynamic decellularization system. Lines represent the hydraulic circuit, which includes infusion and recirculation 
subsections (solid lines) driven by a peristaltic pump and draining subsection (dashed lines) driven by atmospheric pressure. 
 
LIVER DECELLULARIZATION 
For 1% Triton X-100 we added 10 ml to a 1.000 ml bottle, so 990 ml deionized water and we shake 
the bottle twice then we filtered the 1% Triton X-100 solution through a sterile filter. the portal vein 
was pre-inject through 400 ml NaCl 0,9% a 180 nd 800 UI heparin (see Fig. 1). The liver was placed 
in the high-density polyethylene basin and attached to the pump (ISMATEC 405 MCP-Z Standard). 
To performe the decellularization steps we made as followed: deionized (DI) water for 24 hours with 
a flow rate of 7 ml/min; Triton X 1% + Ammonium hydroxide (NH4OH) 0,1% for 48 hours a flow 
rate of 10 ml/min; DI for 24 hours 10 ml/min; Triton X 1% + Ammonium hydroxide (NH4OH) 0,1% 
for 24 hours; DI for 24 hours 10 ml/min. We disinfected the scaffold with peracetic acid for 30 
minutes at 12 ml/min, then we washed the scaffold with sterile NaCl 0,9% for 2 h. Final procedure 
was a light source to trans illuminate the decellularized scaffold and check the macroscopic 
appearance of the parenchyma, its homogeneity and preservation of the vascular tree. (Fig.5).  
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Fig.5 
Trans illumination of the a decellularized left liver lobe. This technique shows the translucent color homogeneity after a complete 
cell removal from the liver parenchyma. 
 
The Scaffold was trated with Peracetic acid for 30 minutes at 12 ml/min; than the scaffold was washed 
with sterile NaCl 0,9% for 2 h. The scaffold was cut in 30 pieces: 27 for BCAA experiment, 1 for 
histology and 1 for DNA contenet assay and 1 as control without cells store in the BCAA-free medium 
(Fig.6) (Tab.1). To detected the cells in the ECM the DAPI (4’,6’-diamidino-2-phenylindole) stain 
for fluorescence microscopy and Trypan blu were achieved. The decellularized liver scaffold was 
preserved in PBS at 4°C before the seeding. 
 
 
Fig.6 Left liver lobe sectioned il 30 ECM scaffolds. Each decellularized organoid has a ID number (see tab.1) for their traceability 
during and after the experiment. 
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ID NUMBER Treatement SCAFFOLD Area 
(mm2) 
1 100 mM DAY 21 52 
2 200 mM DAY 21 55 
3 100 mM DAY 14 54 
4 PCR_ 7 CTR 74 
5 CONTROL DAY 7 44 
6 PCR_7/ 100 83 
7 200 mM DAY 7 51 
8 100 mM DAY 7 66 
9 100 mM DAY 7 53 
10 CONTROL DAY 21 239 
11 200 mM DAY 7 112 
12 200 mM DAY 21 96 
13 PCR_14/200 67 
14 100 mM DAY 14 58 
15 CONTROL DAY 7 43 
16 CONTROL DAY 21 74 
17 PCR_14/100 71 
18 CONTROL DAY 14 73 
19 CONTROL DAY 14 80 
20 PCR_14 CTR 69 
21 PCR_21/200 61 
22 PCR_21/200 49 
23 PCR_21 CTR 103 
24 200 mM DAY 14 55 
25 100 mM DAY 21 138 
26 200 mM DAY 14 41 
27 PCR_7/200 39 
 
Table 1 
The ID number for each scaffold correspond to a treatement with BCAAs or to a PCR sample. The Scaffolds area was espressed in 
mm2 
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CELLS ISOLATION AND CELLS CULTURE  
 
2D CULTURE  
The rabbit liver cell lines were cultured in Dulbecco’s modified Eagle’s medium/ F12 (DMEM) (Life 
Technologies, Waltham, Massachusetts, USA) supplemented with 20% foetal bovine serum (FBS) 
(Life Technologies, Waltham, Massachusetts, USA), 2 ml Antibiotic Antimycotic Solution (100×) 
(Sigma-Aldrich, St. Louis, Missouri, USA), 1 ml L-Glutamine solution (Sigma-Aldrich, St. Louis, 
Missouri United States), 20 µl HGF (R&D systems Minneapolis, Minnesota, USA)76.  
The cells were plated in 4 well culture dishes, daily monitored and the medium was changed every 
two days. Upon reaching the confluence after 15 days, cells were trypsinized, centrifuged and 
resuspended in 5 ml of culture medium. From this solution, 6.6 µl were collected and loaded in a 
specific counting chamber (KOVA Glasstic). Based on the number of cells counted, a diluition with 
the culture medium was carried out in order to obtain a concentration of 120'000 cells per ml. 
Subsequently, cells present in this solution were plated in 4 wells plates (Nunc) on 0,1% porcine 
gelatin (Sigma), with a volume equal to 0,5 ml per well (60'000 cells per well). The various amino 
acids were solubilized to reach final concentrations of 2 mM, 10 mM, 50 mM, and 100 mM as 
compared with complete media alone. 
 
3D CULTURE 
T 75 flask was prepared adding 1.5 ml of sterile 0.1% porcine gelatin and waiting 2 hours to coat the 
surface at room temperature. We washed liver biopsies with new PBS, supplemented with 2% 
antibiotic-antimycotic solution and we placed it in a 100 mm Petri dish and cut into approximately 2 
mm3 fragments with sterile scalpels. Than we place fragments in tube containing 30 mL of Trypsin 
solution and gently shake from 10 to 30 min at 37°C. At the end of 30 min, the digested tissue was 
filtered with cell 205 strainer 100µm and collect cells in a new 50 mL tube. Filtered cells were 
centrifuged at 1250 g/min for 5 min at room temperature. Supernatant was remove and the cells were 
resuspended in 11 mL of culture medium. Total 15 ml (11ml medium+ 4 ml pellet). The cells were 
plated in gelatin pre-coated T 75 flasks and culture for 6 hours. After 6 hours centrifugation at 1250 
g/min for 5 min at room temperature and the pellet was resuspended to obtain 1x106 cells 
concentration in 500 µl. Place every single decellularized liver scaffolds in a 35 mm Petri Dishes. We 
seeded the cells directly onto scaffold using a 1000 µl pipette and we inserted the 35 mm Petri Dishes 
containing the ECM and cells in a 100 mm Petri Dish with another 35 mm Petri Dish containing 
deionized water to prevent exsiccation. The scaffold was transfered to the incubator under aseptic 
conditions with (5%) CO2 at 37°C, to encourage cell engrafting and ECM repopulation (Fig. 7). As 
in the 2D culture the the rabbit hepatocytes BCAAs-free medium was: Dulbecco’s modified Eagle’s 
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medium/ F12 (DMEM) (Life Technologies, Waltham, Massachusetts, USA) supplemented with 20% 
foetal bovine serum (FBS) (Life Technologies, Waltham, Massachusetts, USA), 2 ml Antibiotic 
Antimycotic Solution (100×) (Sigma-Aldrich, St. Louis, Missouri, USA), 1 ml L-Glutamine solution 
(Sigma-Aldrich, St. Louis, Missouri United States), 20 µl HGF (R&D systems Minneapolis, 
Minnesota, USA)75.  
  
 
 
 
Figure 7. 
Cells colonize the scaffold (arrows) and form clusters bordering and entering the recellularizing matrix. 
 
BCAA EXPERIMELTAL DESIGN 
The branched chain amino acids with 2:1:1 ratio was solubilized into the cell’s monolayer medium 
culture to reach final concentrations of 2 mM, 10 mM, 50 mM, and 100 mM as compared with 
complete media alone.  
In the 3D hepatocyte model with decellularized liver the BCAAs addiction with 2:1:1 ratio was: 200 
mM, 100 mM, 0 mM as control (Tab.2). 
The liver organoids incubated with the different cell type were evaluate after 7, 14, 21 days of in vitro 
static culture. 
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Table 2 
Time table for the recellularized liver scaffold. 
 
 
DAYS 
OF 
CULTU
RE 
NUMBER OF 
SCAFFOLDS 
CULTURED 
NUMBER OF 
SCAFFOLDS WITH 
CULTURE 
MEDIUM WITH 
FBS 
NUMBER OF 
SCAFFOLDS 
WITH 
CULTURE 
MEDIUM 
WITHOUT FBS 
NUMBER OF 
SCAFFOLDS 
BLOCKED 
1 27 27 0  
2 27 0 0  
3 27 27 0  
4 27 0 0  
5 27 27 0  
6 27 0 0  
7 27 18 9  
8 18 0 0 9 
9 18 18 0  
10 18 0 0  
11 18 18 0  
12 18 0 0  
13 18 18 0  
14 18 9 9  
15 9 0 0 3 
16 9 9 0  
17 9 0 0  
18 9 9 0  
19 9 0 0  
20 9 9 0  
21 9 0 9  
22 9 0 0 3 
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ANALYSIS 
 
FUNCTIONAL ASSAY 
The albumin (Albumin Rabbit ELISA Kit, abcam) and Factor VII (Rabbit coagulation factor VII 
ELISA Kit, CUSABIO) content was determined by enzyme-linked immunosorbent assay. 
Absorbances were measured with a Thermo Scientific Multiskan FC microplate reader (Life 
Technologies, Waltham, Massachusetts, USA).  
Morphological characterization, biochemical analysis medium during culture were evaluated. The 
supernatant of the cell culture was analyzed for transaminase enzyme activity, urea and albumin 
content after overnight culture. The supernatant of was therefore centrifuged at 3000g for 5 minutes 
(4°C). 
Total protein ammount inthe culture medium were misured with chromatographic analysis (Cobas 
Mira, Roche, Basel, Swizerland). 
The cells and organoids damage were misured detecting the ALT, GGT, LDH and ALP enzyme in 
the culture medium with chromatographic analysis (Cobas Mira, Roche, Basel, Swizerland).  
 
PCR ASSAY 
Total RNA was extracted using Trizol (Invitrogen) and DNAse I (Invitrogen) was added in Lysis 
solution at 1:100 concentration as indicated by manufacturer’s instruction. DNA content assay of the 
decellularized liver scaffolds (ID number 28) were achieved with DNA Thermal Cycler. 
The effective removal of genomic DNA from each RNA batch was then confirmed performing a 
standard PCR amplification for β-actin, using genomic DNA as positive control. Only negative 
samples were then reverse transcribed with Superscript™ II Reverse Transcriptase (Invitrogen). 
Activation of transcription factor Oryctolagus cuniculus albumin (ALB), Oryctolagus cuniculus alpha 
fetoprotein (AFP), Oryctolagus cuniculus KIT proto-oncogene receptor tyrosine kinase (KIT), 
Oryctolagus cuniculus hepatocyte nuclear factor 4 alpha (HNF4A), Oryctolagus cuniculus 
coagulation factor VII (F7), Oryctolagus cuniculus IL-6, Oryctolagus cuniculus hepatocyte growth 
factor (HGF), Oryctolagus cuniculus vascular endothelial growth factor (VEGF) and Oryctolagus 
cuniculus transforming growth factor alpha (TGF-α) were examined using consensus 
oligonucleotides of:      
 
Oryctolagus cuniculus albumin (ALB), mRNA 
NCBI Reference Sequence: NM_001082344.1 
OLIGO            start  len      tm     gc%   any    3' seq 
LEFT PRIMER       1488   20   59.97   55.00  3.00  3.00 atctgtccgtggtcctgaac 
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RIGHT PRIMER      1693   20   59.99   55.00  4.00  2.00 ctccgtttctggaagagtgc 
SEQUENCE SIZE: 1996 
INCLUDED REGION SIZE: 1996 
 
PRODUCT SIZE: 206, PAIR ANY COMPL: 5.00, PAIR 3' COMPL: 2.00 
 
Oryctolagus cuniculus alpha fetoprotein (AFP), mRNA 
 
NCBI Reference Sequence: XM_002717026.3 
 
OLIGO            start  len      tm     gc%   any    3' seq 
LEFT PRIMER       1633   20   60.06   50.00  6.00  0.00 ATCTTCCACGCGGATCTATG 
RIGHT PRIMER      1839   20   60.07   50.00  4.00  1.00 AATCAGCTTTGGACCCTCCT 
SEQUENCE SIZE: 1958 
INCLUDED REGION SIZE: 1958 
 
PRODUCT SIZE: 207, PAIR ANY COMPL: 5.00, PAIR 3' COMPL: 1.00 
 
Oryctolagus cuniculus KIT proto-oncogene receptor tyrosine kinase (KIT), mRNA 
 
NCBI Reference Sequence: NM_001329070.1 
OLIGO            start  len      tm     gc%   any    3' seq 
LEFT PRIMER       1646   20   60.03   50.00  5.00  0.00 ccattaagatgggcagagga 
RIGHT PRIMER      1932   20   60.07   55.00  4.00  2.00 gtgattccccaggtagctca 
SEQUENCE SIZE: 2910 
INCLUDED REGION SIZE: 2910 
 
PRODUCT SIZE: 287, PAIR ANY COMPL: 4.00, PAIR 3' COMPL: 1.00 
 
 
PREDICTED: Oryctolagus cuniculus hepatocyte nuclear factor 4 alpha (HNF4A), mRNA 
 
NCBI Reference Sequence: XM_008274469.2 
 
OLIGO            start  len      tm     gc%   any    3' seq 
LEFT PRIMER       1001   20   59.98   55.00  3.00  2.00 gagtatgcctgcctcaaagc 
RIGHT PRIMER      1215   20   59.90   50.00  6.00  3.00 tggatctgctcgatcatctg 
SEQUENCE SIZE: 4465 
INCLUDED REGION SIZE: 4465 
 
PRODUCT SIZE: 215, PAIR ANY COMPL: 3.00, PAIR 3' COMPL: 1.00 
 
 
 
Oryctolagus cuniculus coagulation factor VII (F7), mRNA 
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NCBI Reference Sequence: NM_001082679.1 
OLIGO            start  len      tm     gc%   any    3' seq 
LEFT PRIMER        314   20   59.66   55.00  5.00  0.00 gctcctgtgaggaccaaatc 
RIGHT PRIMER       544   20   59.99   50.00  4.00  2.00 cgcatgggtaatcaactgtg 
SEQUENCE SIZE: 1619 
INCLUDED REGION SIZE: 1619 
 
PRODUCT SIZE: 231, PAIR ANY COMPL: 4.00, PAIR 3' COMPL: 1.00 
 
 
 
PRIMER DISEGNATI per analisi sangue su conigli 
 
 
Oryctolagus cuniculus IL-6 mRNA, complete cds 
GenBank: DQ680161.1 
 
OLIGO            start  len      tm     gc%   any    3' seq 
LEFT PRIMER        385   20   59.98   55.00  4.00  0.00 CTTCAGGCCAAGTTCAGGAG 
RIGHT PRIMER       583   20   60.12   55.00  4.00  0.00 AGTGGATCGTGGTCGTCTTC 
SEQUENCE SIZE: 726 
INCLUDED REGION SIZE: 726 
 
PRODUCT SIZE: 199, PAIR ANY COMPL: 4.00, PAIR 3' COMPL: 2.00 
 
Oryctolagus cuniculus hepatocyte growth factor (HGF), mRNA 
NCBI Reference Sequence: NM_001168707.1 
 
OLIGO            start  len      tm     gc%   any    3' seq 
LEFT PRIMER       1924   20   59.99   50.00  5.00  0.00 GAGAAATGCAGTCAGCACCA 
RIGHT PRIMER      2128   20   60.07   55.00  3.00  0.00 GGACGAAGATACCAGGACGA 
SEQUENCE SIZE: 2193 
INCLUDED REGION SIZE: 2193 
 
PRODUCT SIZE: 205, PAIR ANY COMPL: 3.00, PAIR 3' COMPL: 0.00 
 
Oryctolagus cuniculus vascular endothelial growth factor (VEGF) mRNA, partial cds 
GenBank: AY196796.1 
 
 
OLIGO            start  len      tm     gc%   any    3' seq 
LEFT PRIMER         10   20   59.99   55.00  4.00  1.00 CTACCTCCACCATGCCAAGT 
RIGHT PRIMER       245   20   59.83   50.00  3.00  2.00 CACACTCCAGGCTTTCATCA 
SEQUENCE SIZE: 361 
INCLUDED REGION SIZE: 361 
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PRODUCT SIZE: 236, PAIR ANY COMPL: 3.00, PAIR 3' COMPL: 1.00 
 
 
Oryctolagus cuniculus transforming growth factor alpha mRNA, partial cds 
GenBank: AF333183.1 
 
OLIGO            start  len      tm     gc%   any    3' seq 
LEFT PRIMER         44   19   60.40   57.89  3.00  0.00 AAGCCCTGGAGAACAGCAC 
RIGHT PRIMER       205   20   60.05   55.00  5.00  3.00 CAGAGTGGCAGACACATGCT 
SEQUENCE SIZE: 206 
INCLUDED REGION SIZE: 206 
 
PRODUCT SIZE: 162, PAIR ANY COMPL: 4.00, PAIR 3' COMPL: 3.00 
 
 
MORPHOLOGY 
Briefly, the samples to be processed for standard histology were further fixed in 10% (v/v) phosphate-
buffered formaldehyde for 24h at room temperature, then dehydrated in a graded 50% (v/v), 70% 
(v/v), 95% (v/v) and 100% (v/v) ethanol series, embedded in paraffin and cut into 4 µm-thick sections 
by a microtome. Finally, the sections were stained with Hematoxylin and Eosin, using a standard 
staining protocol, for the evaluation of the morphological structure and their relationships. The 
observations were carried out through the use of an optical microscope Nikon ECLIPSE E600 
(Olympus, Milan, Italy), equipped with digital camera and software for image analysis.  
 
QUANTIFICATION OF THE REPOPULATION OF THE ORGANOID ECM 
After the measurement of the total Area (mm2) of each scaffold, the organoids were sliced at 4 
different levels: first superficial slice at 4 µm, second superficial-mild slice at 104 µm, third deep-
mild slice at 204 µm and fourth deep slice at 304 µm (Fig.8). Each slice was 4 µm thickness as 
standard histological evaluation. Cells count with optical micrioscopy for each slice were achieve. 
To compair the repopulatin onto organoids the total ratio of cells number/Area (mm2) per slice were 
evaluated.      
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Figure.8 
Graphical scheme of the scaffold sampling obtained to count and detect the ECM repopulation. The number represent the slice leves: 
1= histological slice, 4 µm; 2= histological slice, 100 µm; 3= histological slice, 200 µm; 4= histological slice, 300 µm; h= scaffold 
thickness, 500 µm. 
 
 
IMMUNOCYTOCHEMISTRY AND IMMUNOHISTOCHEMISTRY 
Cells were fixed in 4% (wt/vol) paraformaldehyde in PBS (Sigma), rinsed three times in PBS and 
permeabilized with 0,1% and 0,4% (vol/vol) Triton X-100 (Sigma) in PBS, for 20 min. Samples were 
treated with blocking solution containing 5% (vo/vol) BSA and 5% (vol/vol) goat serum in PBS, for 
30 min. Then, cells were incubated with anti-albumin (Abcam) overnight. The day after, cells were 
incubated with suitable secondary antibodies (Alexa Flor® 488) for 60 min. Nuclei were stained with 
4’,6-diamino-2-phenylindole (DAPI, Sigma). Samples were observed under a Nikon Eclipse TE200.  
For immunohistochemistry the samples were treated with the following procedures: deparaffinized 
and hydrated through xylenes or other clearing agents and graded alcohol series; washed for 5 minutes 
in tap water. The unmasking was perform using a Vector® Antigen Unmasking Solution, Citrate-
based, pH 6.0 (H-3300) or Tris-based, pH 9.0 (H-3301); washed in buffer for 5 minutes; incubated 
for 20 minutes with diluted normal blocking serum; bloted excess serum from sections; incubate for 
30 minutes with primary antibody diluted in buffer; washed for 5 minutes in buffer; incubated for 30 
minutes with diluted biotinylated secondary antibody; washed for 5 minutes in buffer; incubated for 
30 minutes with VECTASTAIN® ABC Reagent; wash for 5 minutes in buffer; incubate in peroxidase 
substrate solution.  
 
STATISTICAL ANALYSIS 
Statistical analysis was performed using SPSS (SPSS Inc., Chicago, IL, USA). Statistical differences 
were evaluated by the Kruskal–Wallis test. A P value <0.05 was considered significant. The median 
values of, albumin synthesis, factor VII, total protein AST, ALT, LDH secretion were expressed with 
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charts. 
 
RESULTS 
 
During surgical explant procedures, the liver was considered healthy. It was reddish-brown in color, 
with a soft consistency, and is highly vascular and easily friable. The histology of the normal liver 
reveals a uniform red color sample with lobular architecture present and without any sigh of 
inflammatory infiltration. The central and sublobular veins were normal and presents. Hepatocytes 
were normal with no sign of atrophy or hypertrophy, uniformity and no pigments were noted.   
 
MORPHOLOGICAL OBSERVATION ON THE MONOLAYER HEPATOCYTES 
CULTURE. 
 
Figure 9 shows the morphology of hepatocytes on day 15. As seen in Figures 9A, hepatocytes formed 
an extended monolayer in collagen-coated plastic dishes. The cell attachment was slightly different 
between BCAA-free and BCAA-containing cultures; the cells stretched more on the surface of the 
dish in the latter case compared to the former (Figure 9B). On the BCAAs-fre medium dish, the cells 
were initially weakly attached, agglomerated, and formed densely fusiform packed monolayer.  
However, when BCAAs were added to the medium epithelial layer was not formed (Fig.9).  
 
 
 
 
Figure 9 
Primary rabbit hepatocyte 2D culture before BCAAs treatment. 
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Figure 10 
Immunofluorescence images of primary rabbit hepatocyte 2D culture for 7 days, the cells expressed albumin (red cytoplasm) 
confirming the cells characterization as hepatocytes. 
 
EFFECTS OF THE BCAAS ADDICTION IN MONOLAYER HEPATOCYTES CULTURE  
 
We studied the effects of BCAA on cell growth, albumin and FVII secretion. Figure 2 presents the 
changes in albumin and Factor VII in a collagen-coated dish culture, in which BCAAs were added in 
a FBS-free medium for 48h. No increase in cell prolifertion was observed when BCAAs was added 
to the medium for days of -free culture.  
The albumin and Factor VII production ability was conserved from the all case-control studies, 
revealing a non-significant difference between five groups (p-value >0,05). 
The cell damage marker represents by ALP and LDH were not detected. The total protein (TP) 
amount in the medium were not statistically different within the groups (p-value >0,05), except for 
ALT (p-value <0,05) (Charts1). Hence, our results revealed no difference between monolayer 
cultures in the BCAAs-free compare with BCAAs medium culture.  
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Chart 1 
Box plot of TP (A) and ALT (B) cellular enzyme release (U/L) in the culture medium and the factor VII (A) and albumin (B) 
production expressed in ng/ml and µg/ml 
 
PERFUSION DECELLULARIZATION OF THE RABBIT  
 
Perfusion decellularization of whole rabbit livers liver was achieved by portal perfusion with Triton 
X-100 and other reagents. The PV was successfully cannulated with an 8,5-sheath introducer 8,5 Fr 
cannula and fixed with 3-0 silk sutures. The liver color turned soft red after the blood was washed 
out. After rinsing with distilled water, the liver turned yellowish brown and showed mild swelling. 
During the perfusion of 1% (w/v) Triton X-100/0.1% ammonium hydroxide, liver cells were washed 
out in great numbers, and the liver color quickly became semi-transparent. At the end of the process, 
the liver was transparent and the acellular scaffold retained the gross shape of the liver (Fig.11). The 
vascular system was visualized clearly through the capsule of the acellular scaffold. 
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Figure 11 
Decellularized liver lobe and an enlargement of the left lateral lobe where we can appreciate the intact vasculature structure 
 
 
 
 
MACROSCOPICAL ORGANOIDS EVALUATION  
 
During the growing time, some organoids took a reddish-brown liver color. This changing during the 
culture days were indipendent from the scaffold thikness or size but there was a correlation between 
the color and the number of cells. 
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Figure 12 
Organoid changing from the decellularized macroscopic aspect to the liver organoid aspect. 
 
FUNCTIONAL ASSAY 
The total protein presence in the all cuture conditions were produced/release in a non-significantly 
different amount (p-value< 0,05; Chart 1). The liver enzyme, normaly used as hepatic maker of liver 
damage where significantly higher in the 200-mM concentration on day 21 (Chart.1). The production 
of factor VII (FVII) and albumin was detected in all the cells cultured on the decellularized liver in 
the absence of BCAAs and in BCAAs-free medium. Both proteins were detected at low levels in the 
cells cultured in the BCAAs-free medium. The secretion of FVII increased steadily in both the 100 
mM grups and reached a peak on day 21, and significant differences in the levels of albumin were 
observed between the cells cultured in the BCAAs and in BCAAs-free medium (Chart 3). In the 
presence of 200 mM, the production of ALB was significantly higher than in the cells cultured in the 
100 mM and BCAA-free medium After day 7 a ALB production decrease was observed on the 
following days 14 and 21.  
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Chart 2 
Box plot of LDH (A), ALT (B) nad ALP (C) cellular enzyme release (U/L) in the culture medium. Blue box plot: Controls (7-14-21 
days); Red box plot: BCAAs concentration in the culture medium 100 mM concentration (7-14-21 days); Yellow box plot: BCAAs 
concentration in the culture medium 200 mM (7-14-21 days). 
 
 
 77 
 
 
Chart 3 
Box plot of the albumin (A, B) factor VII (C) production expressed in µg/ml  and ng/ml. Interestingly for the albumin production 
there is a significant and impressive difference between the 200 mM BCAAs concentration at day 7 compared to others groups. Blue 
box plot: Controls (7-14-21 days); Red box plot: BCAAs concentration in the culture medium 100 mM concentration (7-14-21 days); 
Yellow box plot: BCAAs concentration in the culture medium 200 mM (7-14-21 days). 
 
PCR 
Reverse-transcription–polymerase chain reaction analysis showed the expression of Oryctolagus 
cuniculus albumin (ALB), Oryctolagus cuniculus alpha fetoprotein (AFP), Oryctolagus cuniculus 
KIT proto-oncogene receptor tyrosine kinase (KIT), Oryctolagus cuniculus hepatocyte nuclear factor 
4 alpha (HNF4A), Oryctolagus cuniculus coagulation factor VII (F7), Oryctolagus cuniculus IL-6, 
Oryctolagus cuniculus hepatocyte growth factor (HGF), Oryctolagus cuniculus vascular endothelial 
growth factor (VEGF) and Oryctolagus cuniculus transforming growth factor alpha (TGFalpha) by 
day 7-14-21. Expression Oryctolagus cuniculus albumin (ALB), Oryctolagus cuniculus hepatocyte 
nuclear factor 4 alpha (HNF4A), Oryctolagus cuniculus coagulation factor VII (F7), Oryctolagus 
cuniculus hepatocyte growth factor (HGF), and Oryctolagus cuniculus transforming growth factor 
alpha (TGFalpha) was detected at all time points. Organoids were negative for Oryctolagus cuniculus 
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IL-6, Oryctolagus cuniculus alpha fetoprotein (AFP), Oryctolagus cuniculus KIT proto-oncogene 
receptor tyrosine kinase (KIT) and Oryctolagus cuniculus vascular endothelial growth factor (VEGF). 
Normal rabbit liver speciments were used as positive control and ECM as negative control. The DNA 
quantification is represented in the chart 4.  
 
 
 
 
 
Chart. 4 
DNA quantification demonstrated significant DNA reduction in the control groups, an high value in the the 200 mM groups. 
 
 
MORPHOLOGY AND QUANTIFICATION OF THE REPOPULATION OF THE 
ORGANOID ECM 
The number of cells decreased significantly (Chart 5) between 7, 14 and 21 days of culture (p < 0.05). 
Liver ECM were also successfully repopulated with hepatocyte cells, which rapidly engrafted and 
migrated through the scaffold. Repopulation with cells was also characterized by marked Albumin 
positivity indicating hepatocyte-like cells proliferation (Fig.14,15). Interestingly, there was a marked 
decrease in cell number between 7, 14 and 21 days for the control groups, a peak value at 14 days for 
the 100 mM and an increase number of cells between 7, 14 and 21 days for the 200mM concentration 
(Chart 5; p < 0.05). 
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Chart 4 
Box plot plot for the representation of cell proliferation. (A) All groups during 7-14-21 days; red lines connect the median values of 
100 mM groups, yellow lines connect the median values of 200 mM groups, blue lines connect the median values of control groups; 
1 = 100 mM 7 days, 2 = 200 mM 7 days, 3 = CTR 7 days, 4 = 100 mM 14 days, 5 = 200 mM 14 days, 6 = CTR 14 days, 7 = 100 mM 
21 days, 8 = 200 mM 21 days, 9 = CTR 21 days. (B) cell proliferatio during 7-14-21 days considering all the groups. 
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Figure 14 
Histological comparison (10X and 20X magnification) of fresh liver (FL) and decellularized liver (H&E). Examples of recellularized 
organoids: control BCAA-free medium at day 7 (CTR7), 100 mM BCAA medium concentration at day 7 (100 DAY 7), 200 mM 
BCAA medium concentration at day 7 (200 DAY 7) by Hematoxylin and Eosin (H&E). In the CTR 7 on the left there is a vessels 
repopulated with endothelial cells (black arrow). 
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Figure 15 
Expression and distribution of ALB staining in fresh liver (FL) control BCAA-free medium at day 7 (CTR7), 100 mM BCAA 
medium concentration at day 7 (100 DAY 7), 200 mM BCAA medium concentration at day 7 (200 DAY 7). Scale bar for 20X 
magnification 100 µm. 
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DISCUSSION 
 
The BCAA efficacy to counteract different types of disease strongly debilitating have been studied 
in depth by using in vitro and in vivo clinical trials in medicine77,78. The complex mechanisms that 
underlie the catalytic and anabolic activity of these three amino acids are processed and discovered 
by recent studies that associate the regenerative and energetic ability to their dual atitude in the 
glucogenetic to produced energy and their structural role to produce proteins. Moreover, their broad 
constant presence in mammals in the form of essential amino acids is the key note in clinical nutrition, 
suffice it to think that in every animal and human constituent protein the BCAA constitutes 20% of 
the protein from primary to quaternary structures78. 
The connection between nutrition or intergration with BCAA and therapeutic support to counteract 
diseases is close and real. Indeed, the BCAA as a nutritional therapeutc option is well known to 
coadiuvant the treatement of acute and chronic hepatic failure77,79. Mouse and rat represent the most 
exploited and studied in vivo animal model, while for in vitro researches, murine cells culture or 
immortalized cell lines such as HepG2 or primary tumor cell lines80-83. Recently, more space and 
interest was developed for th 3D cultures, especially using artificial matrices or self-composing cells 
to mimic and facilitate an exchange of paracrine signals in mono cell cultures or in co-cultures. This 
latest type, especially hepatic liver culture, allows models to better investigate mechanisms and to 
promote cellular growth by different stem cell lines. 
Technology for producing highly functional liver organoids is developing rapidly. The first successful 
decellularization of a liver tissue was reported in 2004 by Lin and Colleagues84. Scaffold repopulation 
with primary rat hepatocytes revealed a significantly higher albumin and urea synthesis when 
compared to monolayers of the primary hepatocytes cultured on collagen gels, thus suggesting a 
greater functional potential of cells cultured in a 3D scaffold. Since 2004, several other reports have 
described the successful decellularization of rat, rabbit or pig85.  
For the BCAAs evaluation on their role on the liver regeneration and hepatocyte metabolism we 
selected and set up two differents in vitro models: 2D monolayer hepatocyte culture and a 3D culture 
using the upper cited organoid generate by isolated hepatocyte from a native rabbit liver and ECM 
obtain from a eterologous rabbit liver. The decellularized matrix reveal a maintained net vasculature 
and a low DNA level as a good maker for decellularization process. This technique previously 
described86-93 was moderately short, simple and cheap a let to recellularized the scaffold in an 
acceptable decell-recell time for a total 7 days to obtain a liver organoid cultured in a Petri dish. The 
liver cell isolation with a trypsinization method let to obtain a total of  ≃ 19x106 cells. The choice of  
this type of enzymatic method was done for its inexpensiveness and speed procedure, compare with 
the most used collagenase two-steps perfusion94. The enzymaric isolation with trypsin let us to obtain 
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a decellularized matrix faster than non enzymatic procedures, evaluated from a short isolotaion trial 
not reported in this thesis. 
In the 2D cell culture, BCAAs were not significantly predominant on the hepatocyte viability, 
function and proliferation but morphology change drastically before and after tretments. Therefore, 
the difference in response to the BCAAs treatement may be due to the difference in signal 
transduction induced by the morphological change95 induced by the amino acids. The 
fusiform/fibroblastic morphology know as short spindle shape of the hepatocytes is associate to a 
indifferentiated form of the livers parenchymal cells96. The main and most interestin resuls were 
obtained with the 3D culture. Moreover, the liver organoid model let us to compare precisely the 
BCAAs treatment in differents time culture. The monolayer model didn’t allow us to evaluate the 
cells in culture for more than 15 days, where after that cell entered in G0 and sign of apotosys were 
visible. The scaffold recellularized let us to consider the efficacy of BCAAs and evaluate the cells 
capatity to re-populate differents volume of ECM. The scaffold size variable (Tab1)( Fig.6) gave us 
a results and conclusion that to repopulate hepatic scaffolds small variability in its dimensions are not 
a limitation for the cells colonization.  The macroscopical evaluation reveal in some scaffold, after 7 
days of culture, a modification in the colour aspect of the organoids turning brown, similar to liver 
parenchyma (Fig.12). In literature, there is not any information about specific colours of 
recellularized scaffold, we detected that this characteristic is correlated to cellular proliferation, where 
the darkest scaffolds were the most repopulated (Chart 4). Moreover, the chromatographic analysis 
of the enzyme activity in the culture medium revealed a highest ALT, ALP, GGT, LDH values in the 
darkest organoids. At the end, the colour changing show a peack at day 7 of culture, after that moment 
the colour decrese consistently till day 21. These data suggest that the highest enzyme level is 
correlated to the highet repopulation level and both are associated to the highest metabolism and 
organoid cell damage.  
To compare the cell adhesion and proliferation in the differents scaffold we counted the number of 
cells in the different Areas (mm2). Interestingly, cell proliferation at day 7 of BCAAs treatment does 
not create a substantial improvement. At day 14 cells/Area raio improved with 100 mM, contrariwise 
200 mM concentration gave a higher cells number at day 21. In general, therefore, the best time for 
the cells groth turns out to be at day 7 with or without any BCAAs stimulation, while at day 14 there 
was a spread shown by medians with a considerable better value for the concentration of 100 mM. 
These results should be read as a kind of vitro reproduction of what happens in live patients. 
The oxidative damage and cell growth continue over the times culture and increase more and more 
as in the sick animals or human patients. The action of BCAAs is against cellular and organ aging, 
especially against the depletion of those cells called HPC always through a mTOR activation 
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mechanism that allows the cell and organoids to dramatically improve their lives and vitality. 
Therefore, we obtained a decresing in the cells number at day 21 in controls and in 100 mM groups 
and an improvement in the numerosity in the 200 mM groups. A higher BCAAs amount correspond 
to a highest length of cell life without any biophysical cancer transformation. Several tumor 
suppressors, such as p53, p21, p16, Arf, and pRB, function as regulators of senescence, so they act 
as important tumor suppressors. An explanation for the molecular mechanisms of BCAAs to prevent 
cancer incidence was reported by Nakano et al., the BCAAs inhibited insulin-induced hepatic tumor 
cell proliferation by inducing apoptosis through their activities always on mTORC1 and 
mTORC296,97. In the monolayer culture, we had not any differences between the results with or 
without BCAAs addiction. The data obtained from the monolayer primary cell culture revealed our 
initial hypothesis, where the cell metabolic exchange in 2D models is unefficacy to maintain a 
physiological cell metabolism. Indeed, the hepatocyte in monoculture substantially changes its 
morphology95,98 but not expresses the most of its functional characteristics, hence the motivation and 
success redeemed from 3D culture methods such as Matrigel®92. Thanks to our 3D culture, we were 
able to get some interesting results regarding the different behavior of BCAAs. We can say that there 
is a direct correlation between cellular damage and functionality. While there is a consensual 
relationship between the number of cells that repopulated the scaffold and liver damage hepatocyte 
especially between controls and cells stimulated with 200 mM. While in the case of the 100mM 
concentration organoids they behaved exactly in the opposite manner. The cell number/Area ratio 
and the cell damage were inversely proportional. This can be considered valid and supported by the 
role of hepatocytes during the structured system of the liver regeneration98,99. It is further understood 
that the mechanism of replication is the basis of vicariate role of single hepatocytes and progenitor 
cell as explained by recent studies concerning cellular hepatobiliary therapy101. It is therefore 
important to study how the different liver organoids productions are modified without focusing the 
attention on the cell number evaluation for each scaffold. Regarding the difference between ALB 
production and FVII there is a considerable increase the ALB production in the 200 mM samples and 
a balance ratio between cell damagen and cell number in the 100 mM treatment at days 14. 
The difference between albumin production and factor VII lies in the action and functionality that 
these two proteins have in their organization. In fact, the albumin is produced and released by the 
hepatocytes both progenytorse and mature and it is considered a Negative-phase protein. The doubt 
and the issue we raise is how this protein is released is released or produced in vitro, where the cells 
are subjected to extracellular stimuli that are completely different from its natural environment. 
Albumin is produced for many functions and reasons, among the most important we include 
intravascular oncotic pressure and its carrier role of substances. In the case of hepatic or systemic 
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pathologies and disorders, this protein is released in small quantities to allow for increased production 
of all inflammatory protein factors as IL1, IL6, IL8 and TNFα. We chose and selected another maker 
for hepatocytes function as the non-activated form of FVII. This protein is even more specific to 
evaluate the mature hepatocytes and HPC functionality of our organoids than ALB. Factor VII is 
normaly internalized in the hepatocyte or released into the bloodstream or vascular system, so we can 
certainly assert that the levels found in our cultures are unlikely to be overestimated102,103. To support 
our results and therefore the validity of the differences between the case-control groups was the 
statistical evaluation by the Kruskal Wallis test. The culture times are used to create different cellular 
environments. The evaluation beyond the ability to colonize the ECM created a kind of in vitro model 
of suffering cells. The role of BCAAs is evaluated and confirmed to counteract aging by recreating 
in vitro condition of cell damage. It is, therefore, on the basis of these considerations that at this stage 
of my doctoral project we can establish that for a recellularization of a decellulartized liver the best 
dosage of BCAAs was found to be the 200 mM concentration. While for a shorter and stabilized 
culture, the most effective dosage was 100 mM. In this last case, we can talk about stabilized culture 
as the best ratio between production, damage, and cell counts in term of median values. To complete 
and confirm the framework for the production, we have selected RNAm primers that physiologically 
are expresses during different moments of the hepatocyte replication and liver regeneration. The 
expression of albumin using standard PCR and FVII, instead, there are served for the further 
confirmation of the sought ELISA given. All organoids were positive for HNF4, HGF and TGF-α, 
while negative for IL-6, AFP, c-kit and VEGF. This RNAm transcriptional framework is an index of 
a replication activity of the second phase of liver regeneration, studied in literature mainly with in 
vivo murine post-epatectomy of 70% liver resection100. The possibility that selected cells during 
culture were HPC close to differentiation appears to be the most likely one. Indeed, the presence of 
HNF4, HGF, and TGF-α is an index of non-complete hepatocellular differentiation. The HNF4 
marcher is a progenitor marker known. The replicative response and the production of HGF and TGF-
α characterizes hepatocytes in phases not completely mature96,97,100. The HPC phase selection feature 
of the BCAAs may be that stage not yet investigated but explaned by Hiroyuki Koike et al. and Aezam 
Katoonizadeh et al 75,104. Indeed, in literature, the difference between stem cells and HPC is not so 
clear. New published works are trying to evaluate the different role between the so-called stem cells 
and the HPC niche. Our contribut to the literature could be the PCR negative result on the AFP and 
c-kit expressions. AFP and c-kits are usually expressed in young HPCs107 , and the one of the roles 
of BCAAs is given by the ability to select and amplify the cellular response to liver damage. Several 
studies report the ability to help the growth and development of stem cell niches such as MSC 
midollars79. Hiroyuki Koike et al. reported that the metabolic activity of BCAAs is direct and active 
 86 
to the embryonic liver cells by catalytic pathways75. It is well known that all of the mainly catalytic 
pathways of the Bcaa are primarily limited in the adult liver. Instead, in the embryo until the first half 
of gestation Bcat1 and Bcat2, the transaminases catalyzing the first deamination reactions, are widely 
active, then after the second half of gestation drastically decrease75. It is thus clear that in the adult 
patients the BCAAs hepatotoxic protection is also carried out to their energetic role. The three amino 
acid amino acids are absorbed by the gastrointestinal tract, carried to the portal circle and partially 
captured by the liver but not depleted, retaining high post-prandial concentrations in the blood to be 
absorbed and used predominantly by nervous tissue and kidneys. 
We can additionally add that the c-KIT, AFP and VEGF negativity may also be associated with the 
non-carcinogenicity of cultured cells on the scaffold, also reffering the protective factor that BCAAs 
may have against abnormal replication by mutation of the expression of VEGF and TGF beta 1. Thus, 
their anti-cancer role is act augmenting cell growth but inhibiting tumor growth through the 
expression of mTOR and diminishing the functionality in differentiated tumor cells110. 
The choice of the animal model for this study falls from the rabbit as large animal model. The rabbit 
is considered an excellent bridge between the fast metabolism of a murine model and swine model. 
The difficulty in finding material such as antibodies suitable for factor VII and AFP created a little 
gap to confirm more precisely our hypothesis. We believe that this model to date is the most accurate 
and precise to study the regenerative mechanisms of the liver. Moreover, recent studies111 showed 
that the rabbit can be an excellent model to study disease mechanisms and treatments of acute liver. 
This project evaluated the role of BCAAs in hepatocyte replication using 2D and 3D in vitro culture 
as a model allowing us to focus our attention on organ recellularization and discover the 200mM 
concentration with 2: 1: 1 ratio main BCAAs dosage. This study leaves and raises other questions 
that make up a small drop of an ocean of metabolic connections and paracrine signals. Above all, this 
study also wants to help and support the future of organ culture for transplantation purposes. The 
ultimate goal is to understand how the nutrition of the single cell can help to expand the organ's 
availability by creating real biobank for research and clinical purpose to ‘build’ an in vitro organ to 
bypass the great problem of organ rejection. 
 
 
CONCLUSION  
BCAAs as mentioned by Okobayashi and Hiroyuki Koike are active on cell proliferation and 
particularly on metabolism by activating mTOR-linked mechanisms to support production and 
metabolic activity of hepatocytes. Thanks to the results detected we can complete study of Hiroyuki 
et al., confirming the hypothiesis that BCAAs have a direct action on HPC cells. Moreover, these 
amino acids can be a valuable support for bioingeneering, hepatocytes cultures and organoid 
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construction helping to prolong the time culture counteracting the oxidative damage of the cells. The 
future of this research may be to evaluate whether further concentrations can give a further and 
exponential boost. With this part of my PhD project, I can assume that the usefulness and reliability 
of the 3D in vitro model allows greater accuracy and greater data to study the hepatocytes interactions.  
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The sign and hallmarks of liver damage both in clinical and in experimental in vitro studies are 
cellular enzyme predominantly presents in the hepatocytes cytoplasm (ALP, ALT, LDH). The 
hepatocytes in vitro function is mostly represented by albumin and factor VII production. We have 
decided to validate these damage markers and functionalities in clinical and experimental in vitro 
models to better investigate the best therapeutic choice in case of general illness and cachexia. Indeed, 
in the case of serious debilitating diseases, a principal therapeutic failure and a cause of death of 
patients is an incorrect nutritional intake. Choosing an effective diet plan is still a turning point in 
managing the continuous slimming, thus defining the term malnutrition. PN is defined in some cases 
as a true and proper nutritional therapy and not just as an energy support. PN is also a direct route to 
feeding the individual body compartments and organs bypassing the selective gastrointestinal tract. 
Of the three main components of parenteral solutions, amino acids are increasingly considered and 
used1. In this study we started from the evaluation of different amino acid solutions containing 
different amounts of BCAAs, revealing an interesting data not present in the literature. By increasing 
the proportion of amino acids at the expense of lipids and glucose, the liver doesn’t get overloaded 
but has, also, some improvement in the damage markers. The following in vitro study on hepatocyte 
models has allowed us to fill and investigate a BCAA protection mechanism against the liver aligning 
with the recent study of Hiroyuki et al. Due to all the comforting data gathered from the literature we 
decided to select BCAAs as the most important amino acids components in the parenteral solutions.  
This project started from a close collaboration between nutritional and surgical ideas. PN interpolates 
between the two disciplines by combining nutritional knowledge with the metabolic needs of the liver 
during different pathologies. During the first part of my doctoral studies, however, it was always 
present the necessity to focus on the evaluation of the ready to use formulas available on the market. 
The needs to provide and select an in vitro model that can be valid repeatable and easy to use has 
required great efforts to set up and personally validate the different procedures that constituted the 
materials and the methods of the second in vitro project. The main challenge of the clinical study was 
to enroll patients due to manage the high costs for by the owners in relation to the normal clinical 
nutritional procedures. The in vivo project therefore does not want to be a point of arrival but a 
beginning of the evaluation of the PPN both as a scientific veterinary study and as a study in the field 
of translational medicine. As a mental path the doctoral project has seen the real deductive process 
starting from a clinical need to the inverse process of bench-to-bedside. Starting from the clinical 
situation of the animals the liver stress induced by the disease and, eventually by the PN, we built an 
in vitro 2D and 3D liver structures as a model of organ failure; attributing the homeostatic 
modification a "non-natural" environmental condition. In 2D and 3D cultures, cells reside in an 
altered environment that deprives them of those normal chemical exchanges such as hormonal 
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paracrine signals that belong to the living organism. This situation induces the cell to re-establish and 
self-regulate itself to avoid a death and an early cellular apoptosis. 
In conclusion, this doctoral project hasn’t only the peculiarity of creating finished information but 
has the characteristic of opening new doors and new ideas to the relatively new field in hepatology 
and nutrition in the PPN and the possible role of amino acids and in particular the increasingly 
investigated role of BCAAs and their positional effects on liver and hepatic cells. In this study we 
have investigated the importance of the interaction between BCAAs alone or integrated in PN 
solutions and the eventual roles that different amount of amino acids have on liver preservation. 
Results obtained in this study also suggest that the liver organoid culture using decellularized rabbit 
liver could be a valid model to study toxicological compound or, in particular, improve the emerging 
field of the regenerative medicine to grow organoids and transplantable organs. 
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• Congress: Focus on organ perfusion for clinical transplantation, Hotel Michelangelo, 
23/03/2016, Milan 
• Course in Animal experimentation, Istituto Carlo Besta, 29 gennaio 2016 
• Tutor for the course of Base Anatomiche e Tecniche di Chirurgia del Torace (Veterinary 
Anatomy and technique in thoracic surgery), Prof. Fabio Acocella, Via Celoria 10, Medicina 
Veterinaria, V.E.S.P.A. 2015/2016. 
• Tutor for the course of Base Anatomiche e Tecniche di Chirurgia Addominale (Veterinary 
Anatomy and surgical technique), Prof. Fabio Acocella, Via Celoria 10, Medicina Veterinaria, 
V.E.S.P.A. 2015/2016. 
• Tutor for the course of Alimentazione e dietetica animali da compagnia (small animal 
nutrition), Titolare Prof. Valentino Bontempo, Via Celoria 10, Medicina Veterinaria, 
V.E.S.P.A. da 16/10/2015 a 10/12/2015. 
• Tutor for the course di Razionamento animali monogastrici (small animal nutrition), Titolare 
Prof. Valentino Bontempo, Via Celoria 10, Medicina Veterinaria, V.E.S.P.A. da 16/10/2015 
a 10/12/2015. 
• Veterinary service for: OPEN ABDOMEN course for surgeon, Brescia, July 2015. 
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• Veterinary service for: ATOM course for surgeon, Brescia, July 2015. 
• Course in Animal experimentation, Istituto Mario Negri, 3-5 giugno 2015. 
• Shift worker at the small animal hospital of the University of Milan Faculty of Veterinary Medicine.  
• Collaborations with Veterinary Clinic Gambolò, Pavia, Italy, chef medical office dr. Giuliano Colli Lanzi. 
 
Scientific dissemination: 
• Scientific paper: Matteo Ghiringhell, Alessandro Zenobi, Stefano Brizzola, Fulvio Gandolfi, 
Valentino Bontempo, Sandro Rossi, Tiziana A.L. Brevini, Fabio Acocella. Simple and quick 
method to obtain a decellularized, functional liver bioscaffold. Methods in Molecular Biology 
Methods Mol Biol 2017 Nov 4.  
• Thesis Advisor: ‘VALUTAZIONE MORFOLOGICA QUANTITATIVA DI ORGANOIDE 
RICELLULARIZZATO DEL FEGATO’, Luca Allevi, 2016/2017. 
• Scientific Posters: Matteo Ghiringhelli, Stefano Brizzola, Georgia Pennarossa, Tiziana A.L.  
Brevini, Fabio Acocella. Use of 2D and 3D rabbit hepatocyte cultures to investigate 
Branched-Chain Amino Acid effects in liver. First Annual Meeting, COST Action CA16119 
CellFit, “In vitro 3-D total cell guidance and fitness” 12-13 September 2017 Albena Resort, 
Bulgaria.  
• Scientific Poster: Matteo Ghiringhelli, Stefano Brizzola, Filippo Consolo, Tiziana A.L. 
Brevini, Fulvio Gandolfi, Alessia Di Giancamillo, Marco Trovatelli, Camilla Mocchi, 
Angelica Stranieri, Tiziana Vitiello, Eleonora Fusi, Valentino Bontempo, Fabio Acocella. 3D 
culture and normothermic perfusion for liver animal model validation. COST Action BM 
1308 “Sharing Advances on Large Animal Models – SALAM final conference. Advances on 
large animal models: bridging the gap between biomedical research and clinical 
translation September 28-29, 2017, Halle (Saale), DE. 
• Scientific Oral presentation:  Vitali F, Kariuki EK, Gakuya F, Limo C, Ghiringhelli M, 
Ravasio G. Comparison of dexmedetomidine-ketamine and medetomidine-ketamine 
immobilization in free-ranging and captive African lions (Panthera Leo). AVA Autumn 
Meeting Berlin Association of Veterinary Anaesthetists; November 9th-11th 2017.  
• Coccolini F, Acocella F, Morosi L, Brizzola S, Ghiringhelli M, Ceresoli M, Davoli E, 
Ansaloni L, D’Incalci M, Zucchetti M. High Penetration of Paclitaxel in Abdominal Wall of 
Rabbits after Hyperthermic Intraperitoneal Administration of Nab-Paclitaxel Compared to 
Standard Paclitaxel Formulation. Pharm Res. 2017 Jun;34(6):1180-1186. doi: 
10.1007/s11095-017-2132-4. Epub 2017 Feb 28. 
• Scientific Posters: E Fusi, M Ghiringhelli, R Rebecca, A Crotti, C Bianchi, R Rice, R Rizzi, S 
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• Marelli, PA Martino” Effect of lactobacillus acidophilus strain supplementation on nutritional 
status and faecal quality in two canine breeds” ESVCN 20th Congress, 15-17 September 
2016, Berlin, Germany. 
• Scientific Posters: C Macchioni, M Ghiringhelli, ES D’Urso, E Lazzarini, F. Di Cesare, D 
Fonda, D Gioeni and G Ravasio “Resting metabolic rate (rmr) measurements in general 
anaesthesia: reduction provided by dexmedetomidine in dogs” ava Congress Lion, France, 
Prague, Czech Republic, 14-17 September 2016 
• Oral Presentation: P Scarpa, C Palestrini, SP Marelli, M Giraldi, M Ghiringhelli, M Raja, E. 
Fusi” How does the nutritional assessment of dogs vary in a veterinary staff?”, 26TH ECVIM-
CA CONGRESS, GOTEBORG, SWEDEN, 8-10 September 2016. 
• Oral Presentation: Matteo Ghiringhelli, Stefano Brizzola, Fabio Acocella, Davide Caretti,” 
Clinical anatomy of the celiac trunk in the dog: application for elective surgery or surgical 
emergency”, 70° Congresso S.I.S.V.E.T., Palermo, giugno13-16, 2016. 
• Oral Presentation: Matteo Ghiringhelli, Stefano Brizzola, Fabio Acocella, “Vacuum assisted 
closure system in the complex pleural empye- ma: a case report”, 70° Congresso S.I.S.V.E.T., 
Palermo, giugno13-16, 2016. 
• Oral Presentation: Matteo Ghiringhelli, Stefano Brizzola, Fabio Acocella, “Evaluation of 
parenteral nutrition in malnourished dogs”, 70° Congresso S.I.S.V.E.T., Palermo, giugno13-
16, 2016. 
• Scientific Paper: Matteo Ghiringhelli, Stefano Brizzola, Gabriele Barella, Matteo Lodi, 
Stefano Faverzani, Fabio Acocella, “Octreotide as medical therapy of idiopatic chylothorax 
in 3 cats after surgery”, Journal of Small Animal Practice Vol 57 54, May 2016. 
• Scientific Posters: Matteo Ghiringhelli, Stefano Brizzola, Gabriele Barella, Matteo Lodi, 
 Stefano Faverzani, Fabio Acocella “Octrereotide as medical therapy of 
 idiopatic chylothorax in 3 cats after surgery”- 2016 BSAVA Congress 
• Birmingham, UK.  
• Thesis Advisor: “APPORTO VASCOLARE REGIONALE DELL’ARTERIA 
EPIGASTRICA PROFONDA COME BASE DI SVILUPPO DI UN LEMBO 
MIOCUTANEO NEL CANE”, Sesana Alberto, 2014/2015. 
• Thesis Advisor: “MISURAZIONE DEL METABOLISMO BASALE NEL CANE 
MEDIANTE UN CALORIMETRO INDIRETTO PORTATILE: VALUTAZIONE E 
COMPARAZIONE DI PROTOCOLLI ANESTETICO/SEDATIVI”, Eleonora Lazzarini, 
2014/2015. 
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• Thesis Advisor: “VALUTAZIONE DELLA PENETRAZIONE NELLA PARETE 
ADDOMINALE DI ABRAXAME DOPO CHEMIOTERAPIA INTRAPERITONEALE 
IPERTERMICA (HIPEC) NEL CONIGLIO”, Marco Trovatelli, 2014/2015 
• Scientific Abstract: Matteo Ghiringhelli, Georgia Pennarossa, Alessia Di Giancamillo, 
Stefano Brizzola, Tiziana A.L. Brevini, Cinzia Brevini, Fabio Acocella, Valentino Bontempo. 
Derivation of canine hepatocyte in vitro models to study Branched-Chain Amino Acid effects 
on liver functions. HAF journal https://doi.org/10.13130/2283-3927/7025 
• Scientific Poster: ‘Computer tomography of airways and lungs during total liquid ventilation 
with perfloorocarbons” submitted - 41st Annual Congress of the European Society for 
Artificial Organs (ESAO), Gemelli Polyclinics, Rome (Italy), September 17-20, 2014 
• Scientific Poster: “Chylothorax in cat: macroscopic and microscopic anatomical evaluation of 
the complex cisterna chyli - thoracic duct basing on a new surgical approach” - 2014 ACVS 
Surgery Summit in San Diego, California. 
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